CN111254109A - Method for in vitro fertilization and embryo culture of bovine oocytes and transport culture solution - Google Patents
Method for in vitro fertilization and embryo culture of bovine oocytes and transport culture solution Download PDFInfo
- Publication number
- CN111254109A CN111254109A CN202010082017.1A CN202010082017A CN111254109A CN 111254109 A CN111254109 A CN 111254109A CN 202010082017 A CN202010082017 A CN 202010082017A CN 111254109 A CN111254109 A CN 111254109A
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- culture
- sodium
- vitro
- embryo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a method for in vitro fertilization and embryo culture of bovine oocytes and a transport culture solution. In one aspect, the transport medium comprises glycine, alanine, arginine hydrochloride, aspartic acid, cystine dihydrochloride, glutamic acid, L-glutamine, histidine, threonine, tryptophan, tyrosine, valine, ascorbic acid, biotin, choline chloride, calcium pantothenate, folic acid, menadione, and the like. The method for in vitro fertilization and embryo culture of bovine oocytes comprises the following steps: collecting oocytes, maturing in vitro, fertilizing in vitro, culturing embryo in vitro and preserving. The method and the related transport culture solution of the invention show excellent technical effects as described in the specification.
Description
Technical Field
The invention belongs to the technical field of animal breeding, relates to a technology for agriculture-animal husbandry and veterinary breeding, in particular to a method for culturing cattle in vitro fertilization embryos, and further relates to application of a culture solution related to the culture of the cattle in vitro fertilization embryos in culture of the cattle in vitro fertilization embryos. Furthermore, the invention also relates to a method for culturing the cattle in vitro fertilization embryos by using the culture solution related to the cattle in vitro fertilization embryo culture. In particular, the method for culturing bovine in vitro fertilized embryos has excellent technical effects. In particular, the invention relates to a method for in vivo collective oocytes from cattle for in vitro fertilization and embryo culture.
Background
In Vitro Fertilization (In Vitro Fertilization) or (external Fertilization) refers to a technique In which sperm and eggs of a mammal complete a Fertilization process In an environment artificially controlled In Vitro, abbreviated In the english to IVF. Because it is inseparable from the embryo transfer technique (ET), also referred to as IVF-ET for short. In biology, an animal obtained after an in vitro fertilized embryo is transferred to a mother is called a test-tube animal. The technology is successful in the 50 s of the 20 th century, develops rapidly in the last 20 years, and is mature day by day to become an important and conventional animal breeding biotechnology.
The in vitro fertilization technology has important significance for animal reproductive mechanism research, livestock production, medicine, endangered animal protection and the like. For example, using mouse, rat or rabbit as experimental material, the in vitro fertilization technique can be used to study the gametogenesis, fertilization and early embryonic development mechanism of mammals. In the livestock breed improvement, the in vitro fertilization technology provides a cheap and efficient means for embryo production, and has important values for fully utilizing excellent breed resources, shortening the breeding cycle of livestock, accelerating the breed improvement speed and the like. In humans, IVF-ET technology is one of the important measures to treat certain infertility and to overcome sexual linked diseases. In vitro fertilization is also an indispensable component of modern biotechnology, such as mammalian embryo transplantation, cloning, transgenosis, sex control and the like.
With the development of modern agricultural science and technology, in order to make full use of the breeding potential of elite cows and accelerate the genetic breeding process, it becomes necessary to apply a new efficient breeding technology in production practice. In-vivo egg taking (OPU) and In Vitro Fertilization (IVF) are new embryo engineering technologies that have been developed rapidly In the eighties of the twentieth century, and a large number of embryos with definite genetic pedigrees can be obtained by combining the OPU and the IVF, so that the generation interval is shortened. At present, the two technologies become important breeding technologies adopted by farmers in animal husbandry developed countries such as europe, the united states and oceania for expanding stock cow groups. However, with the conventional bovine embryo culture system (CR1aa and SOF liquid), the blastocyst development rate of bovine in vitro fertilization is low, and the embryo quality is far inferior to that of in vivo embryos, so that the pregnancy rate after embryo transfer recipient is low, and therefore how to improve the blastocyst development rate and the embryo quality becomes the focus of in vitro fertilization embryo production and research.
As early as 1878, German Scnenk began to explore the in vitro fertilization technique of mammals using rabbits and guinea pigs as materials. However, in 1951, the in vitro fertilization technology has not been developed in a breakthrough after sperm capacitation was discovered by Zhang Xuanling and Austin, respectively. The cattle in vitro fertilization technology is influenced by the aspects of oocyte in vitro maturation, sperm in vitro capacitation, fertilized egg in vitro culture environment and the like.
The in vitro culture of the embryo is a key link of the IVF technology, and is also the embodiment and the test of the final effect of the oocyte in vitro maturation and in vitro fertilization technology. After in vitro fertilization, a fertilized egg undergoes a number of important changes during its development into a blastocyst, including zygote formation, first cleavage, activation of the embryonic genome, densification, and blastocyst formation. In the process, the change of the external environment can cause the change of gene expression, thereby influencing the normal development and quality of the embryo. Currently, in vitro culture studies of early mammalian embryos focus mainly on improving the composition of the culture medium to meet the nutritional requirements of the embryos at different developmental stages. Two stepwise improved systems were developed based on Charles Rosenkrans 1(CR1) culture Fluid developed by Rosenkrans et al (Rosenkrans, C.F., Jr.and N.L.first, Effect of free acids and vitamins on clearance and maintenance of bovine zygoesin vision.J animal Sci, 1994.72(2): p.434-7) and Synthetic transfusion tube Fluid developed by Tervit et al (Tervit, H.R., D.G.Whittingham, and L.E.Rowson, Successful focus in vitro of sheet and maintenance a.J. Reprod foil, 1972.30(3): p.493-7). According to the research results of Hakan Sagirkaya et al (Sagirkaya, H., et al, Development potential of bovine embryos culture in differential formation and culture conditions. animal reprod Sci,2007.101(3-4): p.225-40) and Somfai et al (Somfai, T., et al, Development of bovine embryos culture in CR1aa and IVD101 medium using differential oxygen delivery and culture system. acta t Hung,2010.58(4): p.465-74), CR1aa culture solution has a good effect on bovine embryo culture and can be widely applied to bovine embryo culture; the results of studies by Thompson, J.G., et al (Thompson, J.G., et al, effects of inhibitors and undercouplers of oxidative phosphorylation reactions and suspensions of bovine embryos cultured in vitro Jreprod Fertil,2000.118(1): p.47-55) and by Jean M.Feugang et al (Feugang, J.M., O.Camigo-Rodriguez, and E.Memil, Culture systems for bovine embryos Science 2009.121(2-3): p.141-149) show that SOF medium is also a suitable Culture system for bovine embryo Culture. The research results of Zhangzhiping et al (Zhangzhiping, anzhixing, Zhang Rust, Zhangong, optimization of cattle embryo culture system, proceedings of northwest university of agriculture and forestry, 2006.34) and Morgan et al (Jun sang nationality, research on cattle oocyte and in vitro embryo culture technology, 2008) also show that the optimized CR1aa and SOF culture solution are both suitable for cattle embryo culture in vitro and achieve good culture effects. Mammalian early embryonic development is a highly coordinated and precisely regulated process. During evolution, gametocytes gradually form a series of molecular cascade networks to ensure that the embryonic development cycle proceeds systematically. During development, the balance of Reactive Oxygen Species (ROS) and antioxidants in and out of the embryo plays a crucial role in early embryo development.
Most biochemical reactions generate ROS, which play important roles both inside and outside the cell, and some ROS function as signaling molecules, but most ROS are harmful to the body. Brooker, R.J., et al (Brooker, R.J., Genetics: analysis and principles (4the d.). McGraw-Hill Science,2011) report that ROS can cause cellular DNA damage, oxidation of unsaturated fatty acids, oxidation of amino acids in proteins, and even inactivation of certain enzymes. In general, ROS exist in four forms, of which H2O2 has a strong oxidizing effect and is the most important factor causing oxidative damage.
A number of studies have shown that Glutathione (GSH), an antioxidant present in a non-protein form, is capable of scavenging various free radicals, superoxide anion free radicals, hydroxyl free radicals, hydrogen peroxide, hypochlorous acid and lipoxygen free radicals, and of maintaining The redox balance inside and outside The cell, environmental GSH and ROS levels inside and outside The cell are two important factors in The development of fertilized eggs, as early as 2000, de Matos et al (de Matos, D.G. and C.C.Furns), The animal of living high yield one (GSH) level after vitamin in vitro synthesis of beta-mercaptohanol, cysteine and cysteine, theriogenology,2000.53(3): p.761-71) have increased The blastocyst rate by The addition of β -mercaptoethanol, cysteine and cystine during in vitro embryo culture.
Although the in vitro fertilization technique can be successfully applied to many mammals, the high production cost and the low efficiency of the in vitro fertilized embryo are caused by the low blastula rate of the in vitro fertilization, so that the wide application of the technique in the rapid propagation practice of the cattle is limited. Therefore, how to reduce the cost and improve the production efficiency and quality of bovine IVF embryos becomes a problem to be solved urgently.
At present, in a cattle in-vitro fertilization technical system, CR1aa and SOF liquid are mainly used as embryo in-vitro culture solutions, and improvement is carried out on the basis, the blastocyst development rates are improved to different degrees, and the average blastocyst development rate is 30-40%. For blastocyst quality, it can be evaluated by the total number of blastocyst cells, the ratio of ICM cell number/total cell number, and the apoptosis rate. The total number of blastocysts varies depending on the stage of the blastocyst, and S.Iwasaki et al (Iwasaki, S.and T.Nakahara, cell number and intention of chromosomal antibodies in bovine blast transferred in vitro followed by tissue culture in vitro or in vivo in clinical science, 1990.33(3): p.669-75) obtained the average total number of blastocysts in early cattle, and the ratio of the number of ICM cells/total number of blastocysts was about 15.8%; andrew J.Watson et al (Watson, A.J., et al, Impact of bone marrow regulation media on embryo transitions, blast definition, cell number, and apoptosis. biol Reprod,2000.62(2): p.355-64) count bovine blastocyst cell apoptosis rates at about 7.7% -13%.
CN103898046B (chinese patent application No. 201410073635.4) discloses a culture solution specially used for bovine in vitro fertilization embryos, the formula of the culture solution is: NaCl 109.5mM, KCl 3.1mM, NaHCO 326.2 mM, MgCl 2.6H 2O 0.8.8 mM, KH2PO31.19mM, sodium pyruvate 0.4mM, glucose 1.5mM, calcium hemi-lactobionate 5mM, 10 v/v% fetal bovine serum, L-glutamine 1mM, 2 v/v% essential amino acids, 1 v/v% nonessential amino acids and glutathione 3mM, formulated in water; the essential amino acid is an aqueous solution prepared by mixing the following amino acids in proportion, wherein the content of each amino acid is as follows: l-arginine hydrochloride 6.32g/L, L-cystine dihydrochloride 1.564g/L, L-histidine hydrochloride monohydrate 2.1g/L, L-isoleucine 2.625g/L, L-leucine 2.62g/L, L-lysine hydrochloride 3.625g/L, L-methionine 0.755g/L, L-phenylalanine 1.65g/L, L-threonine 2.38g/L, L-tryptophan 0.51g/L, L-tyrosine 1.8g/L and L-valine 2.34 g/L; the non-essential amino acid is an aqueous solution prepared by mixing the following amino acids in proportion, wherein the content of each amino acid is as follows: l-alanine 0.89g/L, L-asparagine monohydrate 1.5g/L, L-aspartic acid 1.33g/L, L-glutamic acid 1.47g/L, glycine 0.75g/L, L-proline 1.15g/L and L-serine 1.05 g/L. The results of in vitro fertilization of cattle embryos placed in the culture solution are believed to be obviously superior to the control group without GSH, the blastocyst development rate and the embryo quality are improved, the cost of in vitro embryo production is reduced, an experimental basis is provided for the application of cattle IVF technology to practice, and the genetic breeding process can be greatly accelerated.
The inventor's prior application CN108728404A (application No.: 201810576806.3) discloses a method for culturing bovine in vitro fertilized embryos, which comprises the following steps: (1) collection of oocytes and in vitro maturation in vitro collection: taking slaughterhouse ovaries, placing in a heat-preserving barrel added with double-resistance normal saline, and transporting back to a laboratory within 3h at 31-33 ℃; extracting follicle with surface of 2-8mm, collecting precipitate, picking out oocyte COCs (i.e. cumulus-oocyte complex) with at least 3 layers of cumulus cells under a stereoscopic microscope, washing for 2 times in ovum washing solution, and removing excessive impurities; collecting living bodies: collecting ovum of cattle in vivo, picking up cumulus-oocyte complex (COCs) at least containing 3 layers of cumulus cells under a stereomicroscope from the obtained follicular fluid, and putting into mature culture solution containing HEPES at 38.8 deg.C for 3h for transporting to laboratory; washing COCs obtained by the in vitro collection or the living body collection in oocyte maturation culture solution for 1 time, transferring to new maturation culture solution, and culturing for 22-24h under the conditions of 38.8 ℃, 5.5-6.5% CO2 and saturated humidity; (2) in vitro fertilization, mature COCs are washed in a fertilization culture solution for 1 time, transferred into the fertilization culture solution and placed into an incubator for later use; taking a frozen tubule from liquid nitrogen, and unfreezing in a water bath at 37 ℃; aseptically cutting two ends of the thin tube, injecting semen into 15mL centrifuge tube containing semen preparation culture solution, centrifuging at 328 Xg for 2 times (5 min each time), and discarding supernatant after centrifuging; adding 300 mu L of semen preparation culture solution into the centrifuge tube, re-suspending the sperm precipitate, and taking proper sperm suspension for sperm counting; adding the calculated volume of sperm suspension into the fertilization culture liquid drop containing the oocyte, and placing the culture disc into an incubator to incubate the sperm and the ovum for 16-20h, wherein the culture conditions are 38.8 ℃, 5.5-6.5% CO2 and saturated humidity; (3) after the embryo in-vitro culture and preservation and in-vitro fertilization operations are finished, removing granular cells around the embryo by using an egg stripping needle, putting the embryo into an embryo culture solution for culture, recording the culture conditions as 1 day of the embryo culture, wherein the culture conditions are 38.8 ℃, 6% O2, 88% N2 and saturation humidity, and recording the cleavage rate on the 3 rd day; recording the blastocyst rate on the 7 th day, counting the blastocyst hatching rate (which is the percentage obtained by dividing the number of hatched blastocysts by the number of blastocysts) by the 9 th day, and carrying out quality identification; washing the available embryo in preservation solution for 3 times, balancing in balancing solution for 10min, transferring into freezing solution, loading into embryo according to 5-stage liquid loading method, marking, cooling to-35 deg.C at 0.5 deg.C/min in program cooling instrument, taking out the tubule of embryo rapidly, and placing into liquid nitrogen for freezing.
As is well known, embryo biotechnology is an effective technical means for breeding and rapid propagation of fine cattle, wherein in vivo ovum collection-in vitro embryo production (OPU-IVP) technology can rapidly obtain a large amount of high-quality embryos under in vitro conditions by collecting excellent individual oocytes in vivo and carrying out In Vitro Maturation (IVM), In Vitro Fertilization (IVF), embryo In Vitro Culture (IVC) and the like. Compared with in vivo embryos, the production efficiency of the method is 4-8 times, the breeding potential of excellent dams can be effectively improved, but under general conditions, a cow oocyte donor cow farm is far away from an embryo production laboratory and needs to be transported for hours, and the transportation time and the transportation conditions are very important for maintaining the activity and the quality of oocytes. The method comprises the following steps of firstly, putting collected oocytes in a pre-maturation solution to inhibit the oocytes from maturing, transferring the oocytes to a maturation solution after reaching a laboratory, and putting the oocytes in an incubator for in vitro maturation culture; secondly, the collected oocytes are put in a mature liquid and transported in a micro incubator, and CO is supplied continuously during the transportation2However, it is difficult to maintain the supply of carbon dioxide in a transport state. Therefore, there is a need to develop a culture medium for oocytes that can be used during long-distance transportation without affecting their maturation rate, and without the need to supply CO2And time and cost are saved.
Disclosure of Invention
The invention aims to provide a method for culturing bovine in vitro fertilized embryos with improved performance, and particularly to expect improvement of the production efficiency and the quality of bovine IVF embryos. More specifically, the present invention provides a culture solution specially used for bovine in vitro fertilization embryos and a method for culturing bovine in vitro fertilization embryos by using the culture solution. In addition, the present inventors have also found that a culture medium for culturing bovine in vitro fertilized embryos, which is a culture medium for transporting oocytes over a long distance, surprisingly shows excellent technical effects using the method of the present invention, and have completed the present invention.
To this end, the invention provides, in a first aspect, a method for culturing bovine in vitro fertilized embryos, comprising the steps of:
(1) collection and in vitro maturation of oocytes
a) Collecting in vitro: taking cow ovaries obtained from slaughterhouses, extracting follicle with 2-8mm on the surface, collecting precipitate, picking out oocyte COCs (i.e. cumulus-oocyte complex) at least containing 3 layers of cumulus cell packages under a stereomicroscope, putting the oocyte COCs into transport culture solution containing HEPES, transporting to a laboratory at 38.8 ℃ without carbon dioxide supply within 24 h; or
a) Collecting living bodies: taking follicular fluid from ovum collection source of living cattle, picking out cumulus-oocyte complexes (COCs) at least containing 3 layers of cumulus cells under a stereomicroscope, putting into transport culture solution containing HEPES, transporting to laboratory at 38.8 deg.C without carbon dioxide supply for 24 hr;
b) washing COCs obtained by the in vitro collection or the living body collection in oocyte maturation culture solution for 1 time, transferring to new maturation culture solution, and culturing for 22-24h under the conditions of 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
(2) in vitro fertilization
Washing mature COCs in a fertilization culture solution for 1 time, transferring the COCs into the fertilization culture solution, and putting the COCs into an incubator for later use;
taking a frozen tubule from liquid nitrogen, and unfreezing in a water bath at 37 ℃; aseptically cutting two ends of the thin tube, injecting semen into 15mL centrifuge tube containing semen preparation culture solution, centrifuging at 328 Xg for 2 times (5 min each time), and discarding supernatant after centrifuging; adding 300 mu L of semen preparation culture solution into the centrifuge tube, re-suspending the sperm precipitate, and taking proper sperm suspension for sperm counting;
adding the calculated volume of sperm suspension into the fertilization culture liquid drop containing the oocyte, and placing the culture disc into an incubator to incubate the sperm and the ovum for 16-20h, wherein the culture conditions are 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
(3) embryo in vitro culture and preservation
After the in vitro fertilization operation is finished, removing granular cells around the embryo by using an ovum-peeling needle, putting the granules into embryo culture solution for culture, recording the culture condition as the 1 st day of the embryo culture, wherein the culture condition is 38.8 ℃, 6% O2, 88% N2 and saturation humidity, and recording the cleavage rate on the 3 rd day; recording the blastocyst rate on the 7 th day, counting the blastocyst hatching rate (which is the percentage obtained by dividing the number of hatched blastocysts by the number of blastocysts) by the 9 th day, and carrying out quality identification;
washing the available embryo in preservation solution for 3 times, balancing in balancing solution for 10min, transferring into freezing solution, loading into embryo according to 5-stage liquid loading method, marking, cooling to-35 deg.C at 0.5 deg.C/min in program cooling instrument, taking out the tubule of embryo rapidly, and placing into liquid nitrogen for freezing.
The method according to the first aspect of the present invention, wherein in the step (1) (b), the maturation medium is BY basal medium supplemented with 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL LH, 1. mu.g/mL E2, 20ng/mL EGF.
According to the method of the first aspect of the present invention, in the step (1) (a), the transport culture solution contains glycine 50.0mg/L, L-alanine 25.0mg/L, L-arginine hydrochloride 70.0mg/L, L-aspartic acid 30.0mg/L, L-cystine dihydrochloride 26.0mg/L, L-glutamic acid 75.0mg/L, L-glutamine 100.0mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10.0mg/L, L-isoleucine 40.0mg/L, L-leucine 60.0mg/L, L-lysine hydrochloride 70.0mg/L, L-methionine 15.0mg/L, L-phenylalanine 25.0mg/L, L-proline 40.0mg/L, L-serine 25.0mg/L, L-threonine 30.0mg/L, L-tryptophan 25.0mg/L, L mg/serine 25.0mg/L, L-serine dihydrate 58.0 mg/valine 0 mg/26.01 mg/calcium chloride 0.05 mg/L-calcium chloride, calcium chloride 0.0 mg/vitamin D hydrochloride 0.0.0 mg/05 mg/L25.0 mg/L05 mg/L0.0 mg/L0 mg/L0.05 mg/L, vitamin E chloride L0.0 mg/L0.0.0 mg/L5 mg/L0 mg/L0.5L 0 mg/L8, vitamin E chloride L0.0 mg/L0.5L 0.0.0.0.0.0 mg/L0 mg/L0.7, vitamin E.0.0.5L 0 mg/L0.7L 0 mg/L0.0 mg/L0.7L 0 mg/L0.7L 0mg/LL, sodium dihydrogen phosphate monohydrate 140.0mg/L, adenine sulfate 10.0mg/L, adenosine 5' -phosphate 0.2mg/L, adenosine triphosphate 1.0mg/L, cholesterol 0.2mg/L, glucose 1000.0mg/L, deoxyribose 0.5mg/L, reduced glutathione 0.05mg/L, guanine 0.3mg/L, sodium hypoxanthine 0.354mg/L, phenol red 20.0mg/L, ribose 0.5mg/L, sodium acetate 50.0mg/L, thymine 0.3mg/L, Tween 80 of 20.0mg/L, uracil 0.3mg/L, sodium xanthine 0.3mg/L, and FSH of 0.01/mL, LH of 0.01/mL, E of 1. mu.g/mL250ng/mL EGF, 100ng/mL IGF, 10% gentamicin, 55. mu.g/mL sodium pyruvate, 1.2mM/L cysteine, 3mg/mL BSA, 10mM/L HEPES.
The method according to the first aspect of the invention, wherein the concentration of HEPES, 4-hydroxyethylpiperazine ethanesulfonic acid in the maturation medium is 5-15 mmol/L, such as 10 mmol/L. In the present invention, EGF-epidermal growth factor, FSH-follicle stimulating hormone, FBS-fetal bovine serum, E2-estradiol, LH-luteinizing hormone, IGF-insulin-like growth factor, BSA-bovine serum albumin.
The method according to the first aspect of the present invention, wherein in step (1), the transport culture solution further comprises taurine and zinc gluconate.
The method according to the first aspect of the present invention, wherein in step (1), the concentration of taurine in the transport culture solution is 30-50 mg/L, such as 40mg/L or 45 mg/L.
The method according to the first aspect of the present invention, wherein in step (1), the concentration of zinc gluconate in the transport culture broth is 1 to 3mg/L, for example 2 mg/L. It has surprisingly been found that when defined amounts of taurine and zinc gluconate are added simultaneously to the transport medium according to the invention, the desired maturation of the oocytes is achieved during transport even after transport for up to 24 hours in the absence of carbon dioxide.
The method according to the first aspect of the present invention, wherein in step (2), the fertilization medium is an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM potassium dihydrogen phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 100U/ml penicillin, 100. mu.g/ml streptomycin.
The method according to the first aspect of the present invention, wherein in the step (2), the semen preparation medium is an aqueous solution containing 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM potassium dihydrogen phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 10mM caffeine, 100U/ml penicillin, 100. mu.g/ml streptomycin.
The method according to the first aspect of the present invention, wherein in step (3), the embryo culture fluid comprises: 109.5mM sodium chloride, 3.1mM potassium chloride, 26.2mM sodium bicarbonate, 0.8mM magnesium chloride hexahydrate, 1.19mM monopotassium phosphate, 0.4mM sodium pyruvate, 1.5mM glucose, 5mM calcium half-lactobionate, 2.5 v/v% Fetal Bovine Serum (FBS), 1mM L-glutamine, 2 v/v% essential amino acids, 1 v/v% nonessential amino acids, 3mM glutathione, 0.04 w/v% sodium citrate, 0.02 w/v% maltose in water; the essential amino acid is added by the following amino acids according to the weight proportion: 6.32g of L-arginine hydrochloride, 1.564g of L-cystine dihydrochloride, 2.1g of L-histidine hydrochloride monohydrate, 2.625g of L-isoleucine, 2.62g of L-leucine, 3.625g of L-lysine hydrochloride, 0.755g of L-methionine, 1.65g of L-phenylalanine, 2.38g of L-threonine, 0.51g of L-tryptophan, 1.8g of L-tyrosine and 2.34g of L-valine, wherein the optional amino acids are added in the following weight ratio: 0.89g of L-alanine, 1.5g of L-asparagine monohydrate, 1.33g of L-aspartic acid, 1.47g of L-glutamic acid, 0.75g of glycine, 1.15g of L-proline and 1.05g of L-serine.
According to the first aspect of the present invention, in the step (1), the BY-based culture solution includes 180-220 mg/L calcium chloride, 0.70-0.75 mg/L ferric nitrate nonahydrate, 380-420 mg/L potassium chloride, 90-100 mg/L magnesium sulfate, 6500-7000 mg/L sodium chloride, 130-150 mg/L monosodium phosphate monohydrate, 2000-2500 mg/L sodium bicarbonate, 40-60 mg/L, L-alanine, 20-30 mg/L, L-arginine hydrochloride, 60-80 mg/L, L-aspartic acid, 25-35 mg/L, L-cysteine hydrochloride monohydrate, 0.10-0.12 mg/L, L-cystine dihydrochloride, 20-30 mg/L, L-glutamic acid, 70-80 mg/L glycine, 20-60 mg/L, L-histidine hydrochloride monohydrate, 20-25 mg/6-hydroxyproline, 8mg/L, L-15 mg/0.008-0.8 mg/L methionine hydrochloride, 0.06-0.06 mg/L choline chloride, 0.06-20 mg/L choline chloride, 0.06-12 mg/L choline chloride monohydrate, 0.06-60 mg/L, 0.06-12 mg/L choline chloride monohydrate, 0.8-200 mg/L, 0.8-200 mg/L choline acetate monohydrate, 0.8 mg/L, 0.8-200 mg/L methionine hydrochloride monohydrate, 0.8-200 mg/L methionine hydrochloride, 0.8-5 mg/L0.8-200 mg/L, 0.8-5 mg/L, 0.8-.
According to the method of the first aspect of the present invention, in the step (1), the BY base medium is an aqueous solution containing 200mg/L calcium chloride, 0.72mg/L ferric nitrate nonahydrate, 400mg/L potassium chloride, 97.7mg/L magnesium sulfate, 6800mg/L sodium chloride, 140mg/L sodium dihydrogen phosphate monohydrate, 2200mg/L sodium bicarbonate, 50mg/L, L-alanine 25mg/L, L-arginine hydrochloride 70mg/L, L-aspartic acid 30mg/L, L-cysteine hydrochloride monohydrate, 0.11mg/L, L-cystine dihydrochloride 26mg/L, L-75 mg/L sodium acetate, 50mg/L, L-glycine hydrochloride monohydrate, 21.88mg/L, L-hydroxyproline 10 mg/84-20 mg/L, L-leucine 60mg/L, L-lysine hydrochloride 70mg/L, L-methionine 15mg/L, L-phenylalanine 25 mg/5-proline 40mg/L, L mg/40 mg/24 mg/L serine folate, 0.5mg/L folate hydrochloride, 0.05mg/L adenine, 0.05mg/L sodium folate hydrochloride monohydrate, 0.27 mg/L, 0.5mg/L adenine, 0.8-arginine hydrochloride monohydrate, 27, 0.8-L, 0.8-cysteine hydrochloride monohydrate, 26 mg/L-cystine hydrochloride monohydrate, 26 mg/L-cystine hydrochloride monohydrate, 26 mg/L-26 mg/L, 26 mg/L-cystine hydrochloride monohydrate, 26 mg/L-26 mg/L, 0.8-histidine hydrochloride, 0.8-26 mg/L, 0.8-histidine hydrochloride monohydrate, 26mg/L, 0.8-histidine hydrochloride, 26mg/L, 0.8-histidine hydrochloride, 26mg/L, 3-histidine hydrochloride, 0.8-arginine hydrochloride, 0.8-L, 3-L, 0.8-arginine hydrochloride, 0.8-L, 3-L, 0.8-L, 3mg/L, 3-L, 3mg/L, 0.8-L, 0.
The method according to the first aspect of the present invention, wherein in step (1), the BY basal medium further comprises sodium selenite at a concentration of 0.2-0.3 mg/L, such as 0.25 mg/L; and/or the BY basic culture solution also comprises copper sulfate, and the concentration of the copper sulfate is 0.05-0.1 mg/L (calculated BY anhydrous substance), such as 0.075 mg/L.
In the present invention, for example, in step (3), the preservation solution, equilibration solution, freezing solution and the like for embryos are well known in the art and are readily available from commercial sources, for example, the freezing solution may be FreezeKit sold domestically by Vitroffe, SwedenTMClean (the invention is not specifically illustrated, and the freezing fluid used in the example is FreezekitTMClean, the embryo preservation solution is Whittingham modified Du's phosphate buffer containing 20% bovine serum and 500IU/ml penicillin G potassium, and the equilibrium solution is ES solution from Kitazato Biopharma, Japan).
Further, the second aspect of the present invention provides a transport culture solution for oocyte.
The transport culture solution according to the second aspect of the present invention comprises: glycine 50.0mg/L, L-alanine 25.0mg/L, L-arginine hydrochloride 70.0mg/L, L-aspartic acid30.0mg/L, L-cystine dihydrochloride 26.0mg/L, L-glutamic acid 75.0mg/L, L-glutamine 100.0mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10.0mg/L, L-isoleucine 40.0mg/L, L-leucine 60.0mg/L, L-lysine hydrochloride 70.0mg/L, L-methionine 15.0mg/L, L-phenylalanine 25.0mg/L, L-proline 40.0mg/L, L-serine 25.0mg/L, L-threonine 30.0mg/L, L-tryptophan 10.0mg/L, L-tyrosine disodium salt dihydrate 58.0mg/L, L-valine 25.0mg/L, ascorbic acid 0.05mg/L, biotin 0.01mg/L, choline chloride 0.5mg/L, D-calcium pantothenate 0.01mg/L, 0.01 mg/naphthoquinone 0.01mg/L, calcium chloride 0.0.0 mg/folate 0.0 mg/folate 0.05mg/L, calcium chloride 0.0.0.0.8 mg/folate, calcium chloride 0.0.0.8 mg/folate, calcium chloride250ng/mL EGF, 100ng/mL IGF, 10% gentamicin, 55. mu.g/mL sodium pyruvate, 1.2mM/L cysteine, 3mg/mL BSA, 10mM/L HEPES.
The transport culture solution according to the second aspect of the present invention further comprises taurine and zinc gluconate.
The transport culture solution according to the second aspect of the present invention, wherein the concentration of taurine is 30 to 50mg/L, for example 40mg/L or 45 mg/L.
The transport culture solution according to the second aspect of the present invention, wherein the concentration of zinc gluconate is 1 to 3mg/L, for example 2 mg/L.
Any technical feature possessed by any one aspect of the invention or any embodiment of that aspect is equally applicable to any other embodiment or any embodiment of any other aspect, so long as they are not mutually inconsistent, although appropriate modifications to the respective features may be made as necessary when applicable to each other. Various aspects and features of the disclosure are described further below.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure.
The fetal bovine serum used in the present invention can be easily obtained in a standardized commercial form from the market, and for example, Australian fetal bovine serum (cat # 10099141) from Gibco, New Zealand fetal bovine serum (cat # 10091148), North American fetal bovine serum (cat # 16000044), and Mexico fetal bovine serum (cat # 10437028) can be obtained from various agents. In the experiments in the context of the present invention, the fetal bovine serum used was Australian fetal bovine serum from Gibco (cat # 10099141), unless otherwise specified.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are commercially available products.
Example 1: culture method of cattle in vitro fertilization embryo (in vitro collection)
Reagent
In the specific test of the present invention, the reagents used are described in detail below, unless otherwise specified:
adding double-resistant normal saline: contains normal saline solution of penicillin 400IU/mL and streptomycin 400 mug/mL.
Washing the egg: BY basal medium supplemented with 3mg/mL bovine serum albumin.
Mature culture solution: BY basal medium supplemented with 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL LH, 1. mu.g/mL E2, 20ng/mL EGF.
Maturation medium containing HEPES: BY basal medium supplemented with 15mmol/L HEPES, 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL LH, 1. mu.g/mL E2, 20ng/mL EGF.
Wherein EGF is epidermal growth factor, FSH is follicle stimulating hormone, FBS is fetal bovine serum, E2 is estradiol, and LH is luteinizing hormone.
Fertilization culture solution: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 100U/ml penicillin, 100. mu.g/ml streptomycin.
Preparing a culture solution from semen: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 10mM caffeine, 100U/ml penicillin, 100. mu.g/ml streptomycin.
Embryo culture solution: comprises the following steps: 109.5mM sodium chloride, 3.1mM potassium chloride, 26.2mM sodium bicarbonate, 0.8mM magnesium chloride hexahydrate, 1.19mM monopotassium phosphate, 0.4mM sodium pyruvate, 1.5mM glucose, 5mM calcium half-lactobionate, 10 v/v% Fetal Bovine Serum (FBS), 1mM L-glutamine, 2 v/v% essential amino acids, 1 v/v% nonessential amino acids, 3mM glutathione, sodium citrate 0.04 w/v%, maltose 0.02 w/v% aqueous solution; the essential amino acid is added by the following amino acids according to the weight proportion: 6.32g of L-arginine hydrochloride, 1.564g of L-cystine dihydrochloride, 2.1g of L-histidine hydrochloride monohydrate, 2.625g of L-isoleucine, 2.62g of L-leucine, 3.625g of L-lysine hydrochloride, 0.755g of L-methionine, 1.65g of L-phenylalanine, 2.38g of L-threonine, 0.51g of L-tryptophan, 1.8g of L-tyrosine and 2.34g of L-valine, wherein the optional amino acids are added in the following weight ratio: 0.89g of L-alanine, 1.5g of L-asparagine monohydrate, 1.33g of L-aspartic acid, 1.47g of L-glutamic acid, 0.75g of glycine, 1.15g of L-proline and 1.05g of L-serine.
BY basal medium is aqueous solution containing calcium chloride 200mg/L, ferric nitrate nonahydrate 0.72mg/L, potassium chloride 400mg/L, magnesium sulfate 97.7mg/L, sodium chloride 6800mg/L, sodium dihydrogen phosphate monohydrate 140mg/L, sodium bicarbonate 2200mg/L, sodium acetate 50mg/L, L-alanine 25mg/L, L-arginine hydrochloride 70mg/L, L-aspartic acid 30mg/L, L-cysteine hydrochloride monohydrate 0.11mg/L, L-cystine dihydrochloride 26mg/L, L-glutamic acid 75mg/L, glycine 50mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10mg/L, L-isoleucine 20 mg/42-leucine 60mg/L, L-lysine hydrochloride 70mg/L, L-methionine 15mg/L, L-phenylalanine 25 mg/5-proline 40mg/L, L-serine 25mg/L, L mg/30 mg/24 mg/tryptophan hydrochloride 70mg/L, L mg/460.45 mg/methionine 0mg/L, L mg/phenylalanine 25 mg/5 mg/proline 40mg/L, L mg/serine 25mg/L, L mg/24 mg/L-lysine hydrochloride 0.45 mg/L, choline chloride monohydrate 0.45/L, calcium adenine dinucleotide phosphate monohydrate 0.05mg/L, calcium sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine disodium adenine dinucleotide sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.8 mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine dinucleotide phosphate monohydrate 0.8 mg/L, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride monohydrate 0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride 0.8-cysteine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride, vitamin D0.8-arginine hydrochloride 0.8-arginine hydrochloride, vitamin D.8-arginine hydrochloride monohydrate 0.8-arginine hydrochloride 0.8-cysteine hydrochloride 0..
II, cattle in-vitro fertilization and embryo culture:
step (1), collection and in vitro maturation of oocytes
Placing the obtained cow ovary in a heat-insulating barrel containing double-resistant normal saline, carrying out transportation to the laboratory within 3h at 31-33 ℃ and 5.5-6.5% CO2 and saturated humidity; extracting follicle with surface of 2-8mm, collecting precipitate, picking out oocyte COCs (i.e. cumulus-oocyte complex) with at least 3 layers of cumulus cells under a stereoscopic microscope, washing for 2 times in ovum washing solution, and removing excessive impurities;
washing the obtained COCs in oocyte maturation culture solution for 1 time, transferring to new maturation culture solution, and culturing for 22-24h (actual operation for 24 hr) under the conditions of 38.8 deg.C, 5.5-6.5% CO2, and saturated humidity;
step (2), in vitro fertilization
Washing mature COCs in a fertilization culture solution for 1 time, transferring the COCs into the fertilization culture solution, and putting the COCs into an incubator for later use;
taking a frozen tubule from liquid nitrogen, and unfreezing in a water bath at 37 ℃; aseptically cutting two ends of the thin tube, injecting semen into 15mL centrifuge tube containing semen preparation culture solution, centrifuging at 328 Xg for 2 times (5 min each time), and discarding supernatant after centrifuging; adding 300 mu L of semen preparation culture solution into the centrifuge tube, re-suspending the sperm precipitate, and taking proper sperm suspension for sperm counting;
adding the calculated volume of sperm suspension into the fertilization culture liquid drop containing the oocyte, and placing the culture disc into an incubator to incubate the sperm and the ovum for 16-20h (actual operation is 18 h), wherein the culture conditions are 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
step (3), embryo in vitro culture and preservation
After the in vitro fertilization operation is finished, removing granular cells around the embryo by using an ovum-peeling needle, putting the granules into embryo culture solution for culture, recording the culture condition as the 1 st day of the embryo culture, wherein the culture condition is 38.8 ℃, 6% O2, 88% N2 and saturation humidity, and recording the cleavage rate on the 3 rd day; recording the blastocyst rate on the 7 th day, counting the blastocyst hatching rate (which is the percentage obtained by dividing the number of hatched blastocysts by the number of blastocysts) by the 9 th day, and carrying out quality identification;
washing the available embryo in preservation solution for 3 times, balancing in balancing solution for 10min, transferring into freezing solution, loading into embryo according to 5-stage liquid loading method, marking, cooling to-35 deg.C at 0.5 deg.C/min in program cooling instrument, taking out the tubule of embryo rapidly, and placing into liquid nitrogen for freezing.
Method for differential staining of embryo
1. Blastocysts from day 7 of in vitro culture were selected and fixed with 2% paraformaldehyde for 20 min.
2. The cells were washed twice with phosphate buffered saline (PBS-BSA) containing 0.5% BSA, and placed in a permeabilizing solution (50. mu.l Triton, 5. mu.l Tween 80 and 9.945ml PBS) at room temperature for 30 min.
3. CDX2 protein was able to bind to primary antibodies by treatment with 2M hydrochloric acid at room temperature for 20min, followed by treatment with 100mM Tris-HCl at room temperature for 10 min.
4. Washed three times with PBS-BSA, the blastocysts were placed in blocking solution (1ml goat serum, 5. mu.l Tween 80 and 8.995ml PBS), blocked for 1h at room temperature, and then blocked overnight in a refrigerator at 4 ℃.
5. Discarding the blocking solution, diluting CDX2 primary antibody with the blocking solution at a ratio of 1:200, incubating at room temperature for 2h, discarding the primary antibody dilution, and washing with PBS-BSA for 5min for 3 times.
Caspase-3 primary antibody (available from Cell Signaling Technology) was diluted 1:200 with blocking solution, incubated at room temperature for 2h, the primary antibody dilution was discarded, and washed 3 times with PBS-BSA for 5min each.
7. CDX 2-specific secondary antibody (purchased from Sigma) was diluted 1:200 with blocking solution under exclusion of light and left at room temperature for 1h without light. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
8. Caspase-3 specific secondary antibodies (purchased from Life technologies) were diluted 1:200 with blocking solution under dark conditions and left at room temperature for 1h in the dark. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
9. Cell nuclei were stained with 10. mu.g/mL Hochest 33342 dye, allowed to act at room temperature for 5min, observed under a fluorescent microscope and photographed.
10. The experiment is repeated three times, 10 blasts are randomly selected each time, and the blast quality is evaluated by calculating the apoptosis rate and the number of ICM cells/total number of cells.
The data statistical method comprises the following steps: experimental data were analyzed using the ANOVA program in statistical software SAS V8, and the Duncan' smultiple-range test method judged the significance of differences between treatments, which were considered significant when p < 0.05.
In the present invention, cleavage rate is fertilization cleavage number/fertilization egg number. In the present invention, blastocyst rate is blastocyst number/cleavage embryo number.
Fourth, In Vitro Maturation (IVM) Effect of oocytes-maturation Rate
In step (1) of this example, after the in vitro maturation culture, the oocyte is observed under an inverted microscope, and when the oocyte has the first polar body released, viscous matrix secreted from the cumulus cells is maintained, and the cell layer is significantly expanded, and the cell spreads around the ovum in a substantially radial manner, the oocyte is judged to be mature, the number of mature oocytes is recorded, and the maturation rate is calculated.
Five results
In this example, a test was conducted on a cattle of China (Nanyang cattle, working breed). As a result, the cleavage rate was 88.2%, the morula rate was 64.2%, the blastocyst rate was 50.8%, and the apoptosis rate was 5.6%; in addition, blastocyst hatchability reached 73.4% on day 9. The maturation rate of the oocyte in vitro maturation reaches 88.3 percent.
In a supplementary test, with reference to the method of example 1 above, three types of cattle, holstein cattle (dairy cattle breed), simmental cattle (beef cattle breed), and chinese buffalo (service breed), were tested, and the results were: the cleavage rate is within 84-90%, the morula rate is within 61-65%, the blastocyst rate is within 50-54%, the apoptosis rate is within 3-6%, and the blastocyst hatching rate on day 9 is within 71-76%; the maturation rates of the oocytes of three holstein cattle, Simmental cattle and Chinese buffalo in vitro maturation are 84.5%, 79.5% and 73.2%, respectively.
Example 2: culture method of cow in vitro fertilization embryo (Living body collection)
Reagent
In the specific test of the present invention, the reagents used are described in detail below, unless otherwise specified:
adding double-resistant normal saline: contains normal saline solution of penicillin 400IU/mL and streptomycin 400 mug/mL.
Washing the egg: BY basal medium supplemented with 3mg/mL bovine serum albumin.
Mature culture solution: BY basal medium supplemented with 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL LH, 1. mu.g/mL E2, 20ng/mL EGF.
Maturation medium containing HEPES: BY basal medium supplemented with 15mmol/L HEPES, 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL LH, 1. mu.g/mL E2, 20ng/mL EGF.
Wherein EGF is epidermal growth factor, FSH is follicle stimulating hormone, FBS is fetal bovine serum, E2 is estradiol, and LH is luteinizing hormone.
Fertilization culture solution: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 100U/ml penicillin, 100. mu.g/ml streptomycin.
Preparing a culture solution from semen: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 10mM caffeine, 100U/ml penicillin, 100. mu.g/ml streptomycin.
Embryo culture solution: comprises the following steps: 109.5mM sodium chloride, 3.1mM potassium chloride, 26.2mM sodium bicarbonate, 0.8mM magnesium chloride hexahydrate, 1.19mM monopotassium phosphate, 0.4mM sodium pyruvate, 1.5mM glucose, 5mM calcium half-lactobionate, 10 v/v% Fetal Bovine Serum (FBS), 1mM L-glutamine, 2 v/v% essential amino acids, 1 v/v% nonessential amino acids, 3mM glutathione, sodium citrate 0.04 w/v%, maltose 0.02 w/v% aqueous solution; the essential amino acid is added by the following amino acids according to the weight proportion: 6.32g of L-arginine hydrochloride, 1.564g of L-cystine dihydrochloride, 2.1g of L-histidine hydrochloride monohydrate, 2.625g of L-isoleucine, 2.62g of L-leucine, 3.625g of L-lysine hydrochloride, 0.755g of L-methionine, 1.65g of L-phenylalanine, 2.38g of L-threonine, 0.51g of L-tryptophan, 1.8g of L-tyrosine and 2.34g of L-valine, wherein the optional amino acids are added in the following weight ratio: 0.89g of L-alanine, 1.5g of L-asparagine monohydrate, 1.33g of L-aspartic acid, 1.47g of L-glutamic acid, 0.75g of glycine, 1.15g of L-proline and 1.05g of L-serine.
BY basal medium is aqueous solution containing calcium chloride 200mg/L, ferric nitrate nonahydrate 0.72mg/L, potassium chloride 400mg/L, magnesium sulfate 97.7mg/L, sodium chloride 6800mg/L, sodium dihydrogen phosphate monohydrate 140mg/L, sodium bicarbonate 2200mg/L, sodium acetate 50mg/L, L-alanine 25mg/L, L-arginine hydrochloride 70mg/L, L-aspartic acid 30mg/L, L-cysteine hydrochloride monohydrate 0.11mg/L, L-cystine dihydrochloride 26mg/L, L-glutamic acid 75mg/L, glycine 50mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10mg/L, L-isoleucine 20 mg/42-leucine 60mg/L, L-lysine hydrochloride 70mg/L, L-methionine 15mg/L, L-phenylalanine 25 mg/5-proline 40mg/L, L-serine 25mg/L, L mg/30 mg/24 mg/tryptophan hydrochloride 70mg/L, L mg/460.45 mg/methionine 0mg/L, L mg/phenylalanine 25 mg/5 mg/proline 40mg/L, L mg/serine 25mg/L, L mg/24 mg/L-lysine hydrochloride 0.45 mg/L, choline chloride monohydrate 0.45/L, calcium adenine dinucleotide phosphate monohydrate 0.05mg/L, calcium sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine disodium adenine dinucleotide sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.8 mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine dinucleotide phosphate monohydrate 0.8 mg/L, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride monohydrate 0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride 0.8-cysteine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride, vitamin D0.8-arginine hydrochloride 0.8-arginine hydrochloride, vitamin D.8-arginine hydrochloride monohydrate 0.8-arginine hydrochloride 0.8-cysteine hydrochloride 0..
II, cattle in-vitro fertilization and embryo culture:
step (1), collection and in vitro maturation of oocytes
Taking follicular fluid from ovum collection source of living cattle, picking out cumulus-oocyte complex (COCs) at least containing 3 layers of cumulus cells under a stereomicroscope, placing into mature culture solution containing HEPES, and transporting to laboratory at 38.8 deg.C, 5.5-6.5% CO2, saturation humidity, within 3 h;
washing the obtained COCs in oocyte maturation culture solution for 1 time, transferring to new maturation culture solution, and culturing for 22-24h (actual operation for 24 hr) under the conditions of 38.8 deg.C, 5.5-6.5% CO2, and saturated humidity;
step (2), in vitro fertilization
Washing mature COCs in a fertilization culture solution for 1 time, transferring the COCs into the fertilization culture solution, and putting the COCs into an incubator for later use;
taking a frozen tubule from liquid nitrogen, and unfreezing in a water bath at 37 ℃; aseptically cutting two ends of the thin tube, injecting semen into 15mL centrifuge tube containing semen preparation culture solution, centrifuging at 328 Xg for 2 times (5 min each time), and discarding supernatant after centrifuging; adding 300 mu L of semen preparation culture solution into the centrifuge tube, re-suspending the sperm precipitate, and taking proper sperm suspension for sperm counting;
adding the calculated volume of sperm suspension into the fertilization culture liquid drop containing the oocyte, and placing the culture disc into an incubator to incubate the sperm and the ovum for 16-20h (actual operation is 18 h), wherein the culture conditions are 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
step (3), embryo in vitro culture and preservation
After the in vitro fertilization operation is finished, removing granular cells around the embryo by using an ovum-peeling needle, putting the granules into embryo culture solution for culture, recording the culture condition as the 1 st day of the embryo culture, wherein the culture condition is 38.8 ℃, 6% O2, 88% N2 and saturation humidity, and recording the cleavage rate on the 3 rd day; recording the blastocyst rate on the 7 th day, counting the blastocyst hatching rate (which is the percentage obtained by dividing the number of hatched blastocysts by the number of blastocysts) by the 9 th day, and carrying out quality identification;
washing the available embryo in preservation solution for 3 times, balancing in balancing solution for 10min, transferring into freezing solution, loading into embryo according to 5-stage liquid loading method, marking, cooling to-35 deg.C at 0.5 deg.C/min in program cooling instrument, taking out the tubule of embryo rapidly, and placing into liquid nitrogen for freezing.
Method for differential staining of embryo
1. Blastocysts from day 7 of in vitro culture were selected and fixed with 2% paraformaldehyde for 20 min.
2. The cells were washed twice with phosphate buffered saline (PBS-BSA) containing 0.5% BSA, and placed in a permeabilizing solution (50. mu.l Triton, 5. mu.l Tween 80 and 9.945ml PBS) at room temperature for 30 min.
3. CDX2 protein was able to bind to primary antibodies by treatment with 2M hydrochloric acid at room temperature for 20min, followed by treatment with 100mM Tris-HCl at room temperature for 10 min.
4. Washed three times with PBS-BSA, the blastocysts were placed in blocking solution (1ml goat serum, 5. mu.l Tween 80 and 8.995ml PBS), blocked for 1h at room temperature, and then blocked overnight in a refrigerator at 4 ℃.
5. Discarding the blocking solution, diluting CDX2 primary antibody with the blocking solution at a ratio of 1:200, incubating at room temperature for 2h, discarding the primary antibody dilution, and washing with PBS-BSA for 5min for 3 times.
Caspase-3 primary antibody (available from Cell Signaling Technology) was diluted 1:200 with blocking solution, incubated at room temperature for 2h, the primary antibody dilution was discarded, and washed 3 times with PBS-BSA for 5min each.
7. CDX 2-specific secondary antibody (purchased from Sigma) was diluted 1:200 with blocking solution under exclusion of light and left at room temperature for 1h without light. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
8. Caspase-3 specific secondary antibodies (purchased from Life technologies) were diluted 1:200 with blocking solution under dark conditions and left at room temperature for 1h in the dark. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
9. Cell nuclei were stained with 10. mu.g/mL Hochest 33342 dye, allowed to act at room temperature for 5min, observed under a fluorescent microscope and photographed.
10. The experiment is repeated three times, 10 blasts are randomly selected each time, and the blast quality is evaluated by calculating the apoptosis rate and the number of ICM cells/total number of cells.
The data statistical method comprises the following steps: experimental data were analyzed using the ANOVA program in statistical software SAS V8, and the Duncan' smultiple-range test method judged the significance of differences between treatments, which were considered significant when p < 0.05.
In the present invention, cleavage rate is fertilization cleavage number/fertilization egg number. In the present invention, blastocyst rate is blastocyst number/cleavage embryo number.
Fourth, In Vitro Maturation (IVM) Effect of oocytes-maturation Rate
In step (1) of this example, after the in vitro maturation culture, the oocyte is observed under an inverted microscope, and when the oocyte has the first polar body released, viscous matrix secreted from the cumulus cells is maintained, and the cell layer is significantly expanded, and the cell spreads around the ovum in a substantially radial manner, the oocyte is judged to be mature, the number of mature oocytes is recorded, and the maturation rate is calculated.
Five results
In this example, a test was conducted on a cattle of China (Nanyang cattle, working breed). As a result, the cleavage rate was 88.4%, the morula rate was 64.7%, the blastocyst rate was 50.3%, and the apoptosis rate was 5.1%; in addition, blastocyst hatchability reached 74.4% on day 9. The maturation rate of the oocyte in vitro maturation reaches 89.6 percent.
In a supplementary test, with reference to the method of example 2 above, three types of cattle, holstein cattle (dairy cattle breed), simmental cattle (beef cattle breed), and chinese buffalo (service breed), were tested, and the results were: the cleavage rate is within the range of 85-90%, the morula rate is within the range of 62-65%, the blastocyst rate is within the range of 51-54%, the apoptosis rate is within the range of 4-6%, and the blastocyst hatching rate on day 9 is within the range of 71-75%; the in vitro maturation rate of oocytes of three holstein cattle, Simmental cattle and Chinese buffalo cattle is 85.2%, 79.1% and 74.32% respectively.
Example 11: culture method of cattle in vitro fertilization embryo (in vitro harvest)Collection)
The main difference between this example and example 1 above is that in step (1) the harvested oocytes were placed in transport medium containing HEPES at 38.8 ℃ without carbon dioxide supply and transported back to the laboratory within 24 h.
Reagent
In the specific test of the present invention, the reagents used are described in detail below, unless otherwise specified:
the transport medium used in this example contained 50.0mg/L, L mg-alanine 25.0mg/L, L-arginine hydrochloride 70.0mg/L, L-aspartic acid 30.0mg/L, L-cystine dihydrochloride 26.0mg/L, L-glutamic acid 75.0mg/L, L-glutamine 100.0mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10.0mg/L, L-isoleucine 40.0mg/L, L-leucine 60.0mg/L, L-lysine hydrochloride 70.0mg/L, L-methionine 15.0mg/L, L-histidine 25.0mg/L, L-proline 40.0mg/L, L-serine 25.0mg/L, L-threonine 30.0mg/L, L-tryptophan 10.0mg/L, L-tyrosine dihydrate 58.0mg/L, L-valine 25.0mg/L, ascorbic acid 0 mg/vitamin E0 mg/phenylalanine hydrochloride 0.0 mg/240 mg/L, calcium chloride 0.0.0 mg/1000 mg/folate 0 mg/folate 0.0 mg/240 mg/folate 0.0.0.0 mg/240 mg/L, vitamin E5-arginine hydrochloride monohydrate, 0.0.0.0.0.0.0 mg/240 mg/L0.0.0.0 mg/240 mg/vitamin D, 0 mg/1.8-arginine hydrochloride, 0.0.0.0.0 mg/1.0 mg/8-arginine hydrochloride, 0.0.0.0.0.0 mg/1, 0.0.0 mg/1.0 mg/8-arginine hydrochloride, 0.0.0.0 mg/1.0.0 mg/1.0 mg/1, 0.0 mg/1, 0.8-arginine hydrochloride, 0.0.0.0.0.0 mg/1, 0.0 mg/1, 0.0.0 mg/1.0.0 mg/1, 0.0 mg/8-arginine hydrochloride, 0.0 mg/1, 0 mg/1, 0.8-arginine hydrochloride, 0.0.0.0 mg/1, 0.0.0 mg/1, 0.0.0.0 mg, 0 mg/1, 0.0.0 mg, 0 mg/1, 0 mg/1, 0.0.0.0.0 mg/1, 0 mg/1, 0.8, 0 mg/1, 0mg, 0.8, 5-arginine, 0.8, 1, 0mg, 1, 0, 0.8, 5, 1, 5, 0, 12EGF at 50ng/mL, 100ng/mL IGF, 10% gentamicin, 55 mug/mL sodium pyruvate, 1.2mM/L cysteine, 3mg/mL BSA, 10mM/L HEPES, 40mg/L taurine, and 2mg/L zinc gluconate.
Adding double-resistant normal saline: contains normal saline solution of penicillin 400IU/mL and streptomycin 400 mug/mL.
Washing the egg: BY basal medium supplemented with 3mg/mL bovine serum albumin.
Mature culture solution: BY basal medium supplemented with 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL LH, 1. mu.g/mL E2, 20ng/mL EGF.
HEPES maturation medium: BY basal medium supplemented with 15mmol/L HEPES, 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL mLLH, 1. mu.g/mL E2, 20ng/mL EGF.
Wherein EGF is epidermal growth factor, FSH is follicle stimulating hormone, FBS is fetal bovine serum, E2 is estradiol, and LH is luteinizing hormone.
Fertilization culture solution: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 100U/ml penicillin, 100. mu.g/ml streptomycin.
Preparing a culture solution from semen: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 10mM caffeine, 100U/ml penicillin, 100. mu.g/ml streptomycin.
Embryo culture solution: comprises the following steps: 109.5mM sodium chloride, 3.1mM potassium chloride, 26.2mM sodium bicarbonate, 0.8mM magnesium chloride hexahydrate, 1.19mM monopotassium phosphate, 0.4mM sodium pyruvate, 1.5mM glucose, 5mM calcium half-lactobionate, 10 v/v% Fetal Bovine Serum (FBS), 1mM L-glutamine, 2 v/v% essential amino acids, 1 v/v% nonessential amino acids, 3mM glutathione, sodium citrate 0.04 w/v%, maltose 0.02 w/v% aqueous solution; the essential amino acid is added by the following amino acids according to the weight proportion: 6.32g of L-arginine hydrochloride, 1.564g of L-cystine dihydrochloride, 2.1g of L-histidine hydrochloride monohydrate, 2.625g of L-isoleucine, 2.62g of L-leucine, 3.625g of L-lysine hydrochloride, 0.755g of L-methionine, 1.65g of L-phenylalanine, 2.38g of L-threonine, 0.51g of L-tryptophan, 1.8g of L-tyrosine and 2.34g of L-valine, wherein the optional amino acids are added in the following weight ratio: 0.89g of L-alanine, 1.5g of L-asparagine monohydrate, 1.33g of L-aspartic acid, 1.47g of L-glutamic acid, 0.75g of glycine, 1.15g of L-proline and 1.05g of L-serine.
BY basal medium is aqueous solution containing calcium chloride 200mg/L, ferric nitrate nonahydrate 0.72mg/L, potassium chloride 400mg/L, magnesium sulfate 97.7mg/L, sodium chloride 6800mg/L, sodium dihydrogen phosphate monohydrate 140mg/L, sodium bicarbonate 2200mg/L, sodium acetate 50mg/L, L-alanine 25mg/L, L-arginine hydrochloride 70mg/L, L-aspartic acid 30mg/L, L-cysteine hydrochloride monohydrate 0.11mg/L, L-cystine dihydrochloride 26mg/L, L-glutamic acid 75mg/L, glycine 50mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10mg/L, L-isoleucine 20 mg/42-leucine 60mg/L, L-lysine hydrochloride 70mg/L, L-methionine 15mg/L, L-phenylalanine 25 mg/5-proline 40mg/L, L-serine 25mg/L, L mg/30 mg/24 mg/tryptophan hydrochloride 70mg/L, L mg/460.45 mg/methionine 0mg/L, L mg/phenylalanine 25 mg/5 mg/proline 40mg/L, L mg/serine 25mg/L, L mg/24 mg/L-lysine hydrochloride 0.45 mg/L, choline chloride monohydrate 0.45/L, calcium adenine dinucleotide phosphate monohydrate 0.05mg/L, calcium sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine disodium adenine dinucleotide sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.8 mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine dinucleotide phosphate monohydrate 0.8 mg/L, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride monohydrate 0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride 0.8-cysteine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride, vitamin D0.8-arginine hydrochloride 0.8-arginine hydrochloride, vitamin D.8-arginine hydrochloride monohydrate 0.8-arginine hydrochloride 0.8-cysteine hydrochloride 0..
Second, cattle bodyExternal fertilization and embryo culture:
step (1), collection and in vitro maturation of oocytes
(a) Taking cow ovaries obtained from slaughterhouses, extracting follicles with the surface of 2-8mm, collecting precipitates, picking up oocyte COCs (namely, cumulus-oocyte complex) at least containing 3 layers of cumulus cell packages under a stereomicroscope, putting the oocycs into a transport culture solution containing HEPES, transporting the oocycs to a laboratory at 38.8 ℃ without carbon dioxide supply within 24 hours (in the example, transporting the oocycs to the laboratory for the next step treatment within 15 hours);
(b) washing the obtained COCs in oocyte maturation culture solution for 1 time, transferring to new maturation culture solution, and culturing for 22-24h (actual operation for 24 hr) under the conditions of 38.8 deg.C, 5.5-6.5% CO2, and saturated humidity;
step (2), in vitro fertilization
Washing mature COCs in a fertilization culture solution for 1 time, transferring the COCs into the fertilization culture solution, and putting the COCs into an incubator for later use;
taking a frozen tubule from liquid nitrogen, and unfreezing in a water bath at 37 ℃; aseptically cutting two ends of the thin tube, injecting semen into 15mL centrifuge tube containing semen preparation culture solution, centrifuging at 328 Xg for 2 times (5 min each time), and discarding supernatant after centrifuging; adding 300 mu L of semen preparation culture solution into the centrifuge tube, re-suspending the sperm precipitate, and taking proper sperm suspension for sperm counting;
adding the calculated volume of sperm suspension into the fertilization culture liquid drop containing the oocyte, and placing the culture disc into an incubator to incubate the sperm and the ovum for 16-20h (actual operation is 18 h), wherein the culture conditions are 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
step (3), embryo in vitro culture and preservation
After the in vitro fertilization operation is finished, removing granular cells around the embryo by using an ovum-peeling needle, putting the granules into embryo culture solution for culture, recording the culture condition as the 1 st day of the embryo culture, wherein the culture condition is 38.8 ℃, 6% O2, 88% N2 and saturation humidity, and recording the cleavage rate on the 3 rd day; recording the blastocyst rate on the 7 th day, counting the blastocyst hatching rate (which is the percentage obtained by dividing the number of hatched blastocysts by the number of blastocysts) by the 9 th day, and carrying out quality identification;
washing the available embryo in preservation solution for 3 times, balancing in balancing solution for 10min, transferring into freezing solution, loading into embryo according to 5-stage liquid loading method, marking, cooling to-35 deg.C at 0.5 deg.C/min in program cooling instrument, taking out the tubule of embryo rapidly, and placing into liquid nitrogen for freezing.
Method for differential staining of embryo
1. Blastocysts from day 7 of in vitro culture were selected and fixed with 2% paraformaldehyde for 20 min.
2. The cells were washed twice with phosphate buffered saline (PBS-BSA) containing 0.5% BSA, and placed in a permeabilizing solution (50. mu.l Triton, 5. mu.l Tween 80 and 9.945ml PBS) at room temperature for 30 min.
3. CDX2 protein was able to bind to primary antibodies by treatment with 2M hydrochloric acid at room temperature for 20min, followed by treatment with 100mM Tris-HCl at room temperature for 10 min.
4. Washed three times with PBS-BSA, the blastocysts were placed in blocking solution (1ml goat serum, 5. mu.l Tween 80 and 8.995ml PBS), blocked for 1h at room temperature, and then blocked overnight in a refrigerator at 4 ℃.
5. Discarding the blocking solution, diluting CDX2 primary antibody with the blocking solution at a ratio of 1:200, incubating at room temperature for 2h, discarding the primary antibody dilution, and washing with PBS-BSA for 5min for 3 times.
Caspase-3 primary antibody (available from Cell Signaling Technology) was diluted 1:200 with blocking solution, incubated at room temperature for 2h, the primary antibody dilution was discarded, and washed 3 times with PBS-BSA for 5min each.
7. CDX 2-specific secondary antibody (purchased from Sigma) was diluted 1:200 with blocking solution under exclusion of light and left at room temperature for 1h without light. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
8. Caspase-3 specific secondary antibodies (purchased from Life technologies) were diluted 1:200 with blocking solution under dark conditions and left at room temperature for 1h in the dark. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
9. Cell nuclei were stained with 10. mu.g/mL Hochest 33342 dye, allowed to act at room temperature for 5min, observed under a fluorescent microscope and photographed.
10. The experiment is repeated three times, 10 blasts are randomly selected each time, and the blast quality is evaluated by calculating the apoptosis rate and the number of ICM cells/total number of cells.
The data statistical method comprises the following steps: experimental data were analyzed using the ANOVA program in statistical software SAS V8, and the Duncan' smultiple-range test method judged the significance of differences between treatments, which were considered significant when p < 0.05.
In the present invention, cleavage rate is fertilization cleavage number/fertilization egg number. In the present invention, blastocyst rate is blastocyst number/cleavage embryo number.
Fourth, In Vitro Maturation (IVM) Effect of oocytes-maturation Rate
In step (1) of this example, after the in vitro maturation culture, the oocyte is observed under an inverted microscope, and when the oocyte has the first polar body released, viscous matrix secreted from the cumulus cells is maintained, and the cell layer is significantly expanded, and the cell spreads around the ovum in a substantially radial manner, the oocyte is judged to be mature, the number of mature oocytes is recorded, and the maturation rate is calculated.
Five results
In this example, a test was conducted on a cattle of China (Nanyang cattle, working breed). As a result, the cleavage rate was 86.4%, the morula rate was 66.3%, the blastocyst rate was 51.6%, and the apoptosis rate was 5.3%; in addition, blastocyst hatchability reached 75.1% on day 9. The maturation rate of the oocyte in vitro maturation reaches 87.5 percent.
In a supplementary test (i.e., supplementary test 11A), tests were carried out for three kinds of cattle, holstein cattle (dairy cattle breed), simmental cattle (beef cattle breed), and chinese buffalo (service breed), respectively, with reference to the method of example 11 above, and the results were: the cleavage rate is within the range of 85-90%, the morula rate is within the range of 62-67%, the blastocyst rate is within the range of 50-55%, the apoptosis rate is within the range of 4-6%, and the blastocyst hatching rate on day 9 is within the range of 72-77%; the maturation rates of oocytes in vitro maturation of three holstein cattle, Simmental cattle and Chinese buffalo cattle are 83.3%, 80.6% and 75.6% respectively.
In a supplementary experiment (i.e. supplementary experiment 11B), reference was made to the method of example 11 above, but in step (1) the oocyte COCs were transported in transport medium for 12 and 24 hours respectively to the laboratory for further processing, 2 transport times results: the cleavage rate is within 83-91%, the morula rate is within 57-68%, the blastocyst rate is within 48-57%, the apoptosis rate is within 3-6%, and the blastocyst hatching rate on day 9 is within 69-78%; the maturation rates of oocytes matured in vitro for the two transport times of 12 hours and 24 hours were 87.1% and 84.2%, respectively, which indicates that the transport culture solution used in step (1) can achieve quite high in vitro maturation rates in a relatively long (wide) time range of 12 hours and 24 hours.
In a supplementary experiment (i.e. supplementary experiment 11C), the method of example 11 above was referred to, but in step (1) the transport medium was not supplemented with taurine and the oocytes COCs were transported in the transport medium for 12, 15 and 24 hours respectively back to the laboratory for further processing; under the test condition, the maturation rate of the oocyte in vitro maturation is obviously different from that of the supplement test 11B, and the maturation rates of the three transportation times are respectively 54.5%, 41.5% and 32.8%.
In a supplementary test (i.e., supplementary test 11D), the method of example 11 above was referenced, but in step (1) the transport medium was not supplemented with zinc gluconate, and the oocyte COCs were transported in the transport medium for 12, 15, and 24 hours, respectively, back to the laboratory for further processing; under the test condition, the maturation rate of the oocyte in vitro maturation is obviously different from that of the supplement test 11B, and the maturation rates of the three transportation times are respectively 50.1%, 42.7% and 34.4%.
In a supplementary test (i.e., supplementary test 11E), the method of example 11 above was referenced, but in step (1) neither taurine nor zinc gluconate was added to the transport medium, and the oocytes COCs were transported back to the laboratory for the next step at 12, 15, and 24 hours in the transport medium, respectively; the maturation rate of oocyte in vitro maturation under the test condition is significantly different from that of the supplement test 11B, and the maturation rates of the three transport times are 44.4%, 39.2% and 29.8% respectively.
In a supplemental test (i.e., supplemental test 11F), reference was made to the test conditions for 24 hour transport in supplemental test 11B, supplemental test 11C, supplemental test 11D, and supplemental test 11E, respectively, above, except that a 5.5% carbon dioxide supply was provided during transport; under the test conditions, the maturation rates of the oocytes in vitro are respectively 88.2%, 71.4%, 73.6% and 70.4%.
The results show that the maturation rate of the oocytes obtained in vitro maturation in the step (1) of the method of the invention under different conditions is obviously different: the high maturation rate can be maintained even when the transport culture solution to which both taurine and zinc gluconate are added is transported for 24 hours under the condition of no carbon dioxide supply, while the maturation rate is considerably low when the culture solution to which both taurine and zinc gluconate are not added is transported under the condition of no carbon dioxide supply. This indicates that the simultaneous addition of the two reagents to the transport medium is very beneficial for the in vitro maturation of oocytes during transport, especially for environments where carbon dioxide is not available during transport.
Example 12: culture method of cow in vitro fertilization embryo (Living body collection)
The main difference between this example and example 2 above is that in step (1) the harvested oocytes were placed in transport medium containing HEPES at 38.8 ℃ without carbon dioxide supply and transported back to the laboratory within 24 h.
Reagent
In the specific test of the present invention, the reagents used are described in detail below, unless otherwise specified:
the transport medium used in this example contained: glycine 50.0mg/L, L-alanine 25.0mg/L, L-arginine hydrochloride 70.0mg/L, L-aspartic acid 30.0mg/L, L-cystine dihydrochloride 26.0mg/L, L-glutamic acid 75.0mg/L, L-glutamine 100.0mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10.0mg/L, L-isoleucine 40.0mg/L, L-leucine 60.0mg/L, L-lysine hydrochloride 70.0mg/L, L-methionine 15.0mg/L, L-phenylalanine 25.0mg/L, L-proline 40.0mg/L, L-serine 25.0mg/L, L-threonine 30.0mg/L, L-tryptophan 10.0mg/L, L-tyrosine disodium salt dihydrate 58.0mg/L, L-valine 25.0mg/L0.05mg/L ascorbic acid, 0.01mg/L biotin, 0.5mg/L, D-calcium pantothenate, 0.01mg/L choline chloride, 0.01mg/L folic acid, 0.01mg/L menadione, 0.025mg/L nicotinamide, 0.025mg/L nicotinic acid, 0.05mg/L para-aminobenzoic acid, 0.025mg/L pyridoxal hydrochloride, 0.025mg/L pyridoxine hydrochloride, 0.01mg/L riboflavin, 0.01mg/L thiamine hydrochloride, 0.1mg/L vitamin A acetate, 0.1mg/L vitamin D2, i.e., calcitol, 0.01mg/L α -tocopherol sodium phosphate, 0.05mg/L inositol, 200.0mg/L anhydrous calcium chloride, 0.7mg/L iron nonahydrate, 97.67mg/L anhydrous magnesium sulfate, 400.0mg/L potassium chloride, 2mg/L sodium chloride, 0.539, 0.01mg/L calcium chloride, 0.0.0.0 mg/L anhydrous calcium chloride, 0.0.0.0 mg/L adenine, 0.7mg/L, 0.140 mg/L, 0.80 mg/L glutathione L, 0.20 mg/L adenine sodium lactate, 0.20 mg/L, 3mg/L adenine sodium acetate, 0.80 mg/L, 0.20 mg/L, 3.80 mg/L, 3.8 mg/L adenine sodium adenine, 3.8 mg/L250ng/mL EGF, 100ng/mL IGF, 10% gentamicin, 55. mu.g/mL sodium pyruvate, 1.2mM/L cysteine, 3mg/mL BSA, 10mM/L HEPES, as well as 45mg/L taurine and 2mg/L zinc gluconate.
Adding double-resistant normal saline: contains normal saline solution of penicillin 400IU/mL and streptomycin 400 mug/mL.
Washing the egg: BY basal medium supplemented with 3mg/mL bovine serum albumin.
Mature culture solution: BY basal medium supplemented with 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL LH, 1. mu.g/mL E2, 20ng/mL EGF.
HEPES maturation medium: BY basal medium supplemented with 15mmol/L HEPES, 100mL/L FBS, 10. mu.g/mL FSH, 10. mu.g/mL mLLH, 1. mu.g/mL E2, 20ng/mL EGF.
Wherein EGF is epidermal growth factor, FSH is follicle stimulating hormone, FBS is fetal bovine serum, E2 is estradiol, and LH is luteinizing hormone.
Fertilization culture solution: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 100U/ml penicillin, 100. mu.g/ml streptomycin.
Preparing a culture solution from semen: an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM monopotassium phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 10mM caffeine, 100U/ml penicillin, 100. mu.g/ml streptomycin.
Embryo culture solution: comprises the following steps: 109.5mM sodium chloride, 3.1mM potassium chloride, 26.2mM sodium bicarbonate, 0.8mM magnesium chloride hexahydrate, 1.19mM monopotassium phosphate, 0.4mM sodium pyruvate, 1.5mM glucose, 5mM calcium half-lactobionate, 10 v/v% Fetal Bovine Serum (FBS), 1mM L-glutamine, 2 v/v% essential amino acids, 1 v/v% nonessential amino acids, 3mM glutathione, sodium citrate 0.04 w/v%, maltose 0.02 w/v% aqueous solution; the essential amino acid is added by the following amino acids according to the weight proportion: 6.32g of L-arginine hydrochloride, 1.564g of L-cystine dihydrochloride, 2.1g of L-histidine hydrochloride monohydrate, 2.625g of L-isoleucine, 2.62g of L-leucine, 3.625g of L-lysine hydrochloride, 0.755g of L-methionine, 1.65g of L-phenylalanine, 2.38g of L-threonine, 0.51g of L-tryptophan, 1.8g of L-tyrosine and 2.34g of L-valine, wherein the optional amino acids are added in the following weight ratio: 0.89g of L-alanine, 1.5g of L-asparagine monohydrate, 1.33g of L-aspartic acid, 1.47g of L-glutamic acid, 0.75g of glycine, 1.15g of L-proline and 1.05g of L-serine.
BY basal medium is aqueous solution containing calcium chloride 200mg/L, ferric nitrate nonahydrate 0.72mg/L, potassium chloride 400mg/L, magnesium sulfate 97.7mg/L, sodium chloride 6800mg/L, sodium dihydrogen phosphate monohydrate 140mg/L, sodium bicarbonate 2200mg/L, sodium acetate 50mg/L, L-alanine 25mg/L, L-arginine hydrochloride 70mg/L, L-aspartic acid 30mg/L, L-cysteine hydrochloride monohydrate 0.11mg/L, L-cystine dihydrochloride 26mg/L, L-glutamic acid 75mg/L, glycine 50mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10mg/L, L-isoleucine 20 mg/42-leucine 60mg/L, L-lysine hydrochloride 70mg/L, L-methionine 15mg/L, L-phenylalanine 25 mg/5-proline 40mg/L, L-serine 25mg/L, L mg/30 mg/24 mg/tryptophan hydrochloride 70mg/L, L mg/460.45 mg/methionine 0mg/L, L mg/phenylalanine 25 mg/5 mg/proline 40mg/L, L mg/serine 25mg/L, L mg/24 mg/L-lysine hydrochloride 0.45 mg/L, choline chloride monohydrate 0.45/L, calcium adenine dinucleotide phosphate monohydrate 0.05mg/L, calcium sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine disodium adenine dinucleotide sulfate monohydrate 0.05mg/L, calcium chloride monohydrate 0.8 mg/L, calcium chloride monohydrate 0.05mg/L, calcium adenine dinucleotide phosphate monohydrate 0.8 mg/L, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride monohydrate 0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride 0.8-cysteine hydrochloride, vitamin D0.8-cysteine hydrochloride 0.8-arginine hydrochloride, vitamin D0.8-cysteine hydrochloride monohydrate 0.8-arginine hydrochloride, vitamin D0.8-arginine hydrochloride 0.8-arginine hydrochloride, vitamin D.8-arginine hydrochloride monohydrate 0.8-arginine hydrochloride 0.8-cysteine hydrochloride 0..
II, cattle in-vitro fertilization and embryo culture:
step (1), collection and in vitro maturation of oocytes
(a) Taking follicular fluid from ovum of living cattle, picking out cumulus-oocyte complexes (COCs) at least containing 3 layers of cumulus cell packages under a stereomicroscope, putting the cumulus-oocyte complexes into a transportation culture solution containing HEPES, transporting the cumulus-oocyte complexes to a laboratory at 38.8 ℃ without carbon dioxide supply within 24h (in the example, transporting the cumulus-oocyte complexes to the laboratory for the next step in 15 h);
(b) washing the obtained COCs in oocyte maturation culture solution for 1 time, transferring to new maturation culture solution, and culturing for 22-24h (actual operation for 24 hr) under the conditions of 38.8 deg.C, 5.5-6.5% CO2, and saturated humidity;
step (2), in vitro fertilization
Washing mature COCs in a fertilization culture solution for 1 time, transferring the COCs into the fertilization culture solution, and putting the COCs into an incubator for later use;
taking a frozen tubule from liquid nitrogen, and unfreezing in a water bath at 37 ℃; aseptically cutting two ends of the thin tube, injecting semen into 15mL centrifuge tube containing semen preparation culture solution, centrifuging at 328 Xg for 2 times (5 min each time), and discarding supernatant after centrifuging; adding 300 mu L of semen preparation culture solution into the centrifuge tube, re-suspending the sperm precipitate, and taking proper sperm suspension for sperm counting;
adding the calculated volume of sperm suspension into the fertilization culture liquid drop containing the oocyte, and placing the culture disc into an incubator to incubate the sperm and the ovum for 16-20h (actual operation is 18 h), wherein the culture conditions are 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
step (3), embryo in vitro culture and preservation
After the in vitro fertilization operation is finished, removing granular cells around the embryo by using an ovum-peeling needle, putting the granules into embryo culture solution for culture, recording the culture condition as the 1 st day of the embryo culture, wherein the culture condition is 38.8 ℃, 6% O2, 88% N2 and saturation humidity, and recording the cleavage rate on the 3 rd day; recording the blastocyst rate on the 7 th day, counting the blastocyst hatching rate (which is the percentage obtained by dividing the number of hatched blastocysts by the number of blastocysts) by the 9 th day, and carrying out quality identification;
washing the available embryo in preservation solution for 3 times, balancing in balancing solution for 10min, transferring into freezing solution, loading into embryo according to 5-stage liquid loading method, marking, cooling to-35 deg.C at 0.5 deg.C/min in program cooling instrument, taking out the tubule of embryo rapidly, and placing into liquid nitrogen for freezing.
Method for differential staining of embryo
1. Blastocysts from day 7 of in vitro culture were selected and fixed with 2% paraformaldehyde for 20 min.
2. The cells were washed twice with phosphate buffered saline (PBS-BSA) containing 0.5% BSA, and placed in a permeabilizing solution (50. mu.l Triton, 5. mu.l Tween 80 and 9.945ml PBS) at room temperature for 30 min.
3. CDX2 protein was able to bind to primary antibodies by treatment with 2M hydrochloric acid at room temperature for 20min, followed by treatment with 100mM Tris-HCl at room temperature for 10 min.
4. Washed three times with PBS-BSA, the blastocysts were placed in blocking solution (1ml goat serum, 5. mu.l Tween 80 and 8.995ml PBS), blocked for 1h at room temperature, and then blocked overnight in a refrigerator at 4 ℃.
5. Discarding the blocking solution, diluting CDX2 primary antibody with the blocking solution at a ratio of 1:200, incubating at room temperature for 2h, discarding the primary antibody dilution, and washing with PBS-BSA for 5min for 3 times.
Caspase-3 primary antibody (available from Cell Signaling Technology) was diluted 1:200 with blocking solution, incubated at room temperature for 2h, the primary antibody dilution was discarded, and washed 3 times with PBS-BSA for 5min each.
7. CDX 2-specific secondary antibody (purchased from Sigma) was diluted 1:200 with blocking solution under exclusion of light and left at room temperature for 1h without light. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
8. Caspase-3 specific secondary antibodies (purchased from Life technologies) were diluted 1:200 with blocking solution under dark conditions and left at room temperature for 1h in the dark. The secondary antibody dilutions were discarded in the dark and washed 3 times with PBS for 5min each.
9. Cell nuclei were stained with 10. mu.g/mL Hochest 33342 dye, allowed to act at room temperature for 5min, observed under a fluorescent microscope and photographed.
10. The experiment is repeated three times, 10 blasts are randomly selected each time, and the blast quality is evaluated by calculating the apoptosis rate and the number of ICM cells/total number of cells.
The data statistical method comprises the following steps: experimental data were analyzed using the ANOVA program in statistical software SAS V8, and the Duncan' smultiple-range test method judged the significance of differences between treatments, which were considered significant when p < 0.05.
In the present invention, cleavage rate is fertilization cleavage number/fertilization egg number. In the present invention, blastocyst rate is blastocyst number/cleavage embryo number.
Fourth, In Vitro Maturation (IVM) Effect of oocytes-maturation Rate
In step (1) of this example, after the in vitro maturation culture, the oocyte is observed under an inverted microscope, and when the oocyte has the first polar body released, viscous matrix secreted from the cumulus cells is maintained, and the cell layer is significantly expanded, and the cell spreads around the ovum in a substantially radial manner, the oocyte is judged to be mature, the number of mature oocytes is recorded, and the maturation rate is calculated.
Five results
In this example, a test was conducted on a cattle of China (Nanyang cattle, working breed). As a result, the cleavage rate was 87.1%, the morula rate was 65.3%, the blastocyst rate was 49.7%, and the apoptosis rate was 5.6%; in addition, blastocyst hatchability reached 73.2% on day 9. The maturation rate of the oocyte in vitro maturation reaches 88.2 percent.
In a supplementary test (i.e., supplementary test 12A), tests were carried out for three kinds of cattle, holstein cattle (dairy cattle breed), simmental cattle (beef cattle breed), and chinese buffalo (service breed), respectively, with reference to the method of example 12 above, and the results were: the cleavage rate is within the range of 86-89%, the morula rate is within the range of 63-66%, the blastocyst rate is within the range of 50-54%, the apoptosis rate is within the range of 4-6%, and the blastocyst hatching rate on day 9 is within the range of 70-75%; the maturation rates of the oocytes of three holstein cattle, Simmental cattle and Chinese buffalo in vitro maturation are 84.6%, 79.5% and 76.1%, respectively.
In a supplementary experiment (i.e. supplementary experiment 12B), reference was made to the method of example 12 above, but in step (1) the oocyte COCs were transported in transport medium for 12 and 24 hours respectively to the laboratory for further processing, 2 transport times results: the cleavage rate is within the range of 85-90%, the morula rate is within the range of 59-67%, the blastocyst rate is within the range of 50-58%, the apoptosis rate is within the range of 4-6%, and the blastocyst hatching rate on day 9 is within the range of 70-77%; the maturation rates of oocytes matured in vitro for the two transport times of 12 and 24 hours were 86.8% and 84.0%, respectively, which indicates that the transport medium used in step (1) can achieve a relatively high in vitro maturation rate over a relatively long (wide) time range of 12 and 24 hours.
In a supplementary test (i.e. supplementary test 12C), reference was made to the method of example 12 above, but in step (1) the transport medium was not supplemented with taurine and the oocytes COCs were transported in the transport medium for 12, 15 and 24 hours respectively back to the laboratory for further processing; under the test condition, the maturation rate of the oocyte in vitro maturation is obviously different from that of the supplement test 11B, and the maturation rates of the three transportation times are respectively 52.1%, 43.2% and 35.3%.
In a supplementary test (i.e., supplementary test 12D), the method of example 12 above was referenced, but in step (1) the transport medium was not supplemented with zinc gluconate, and the oocyte COCs were transported in the transport medium for 12, 15, and 24 hours, respectively, back to the laboratory for further processing; under the test condition, the maturation rate of the oocyte in vitro maturation is obviously different from that of the supplement test 11B, and the maturation rates of the three transportation times are respectively 48.2%, 41.7% and 32.5%.
In a supplementary test (i.e., supplementary test 12E), the method of example 12 above was referenced, but in step (1) neither taurine nor zinc gluconate was added to the transport medium, and the oocytes COCs were transported in the transport medium for 12, 15, and 24 hours, respectively, back to the laboratory for further processing; under the test condition, the maturation rate of the oocyte in vitro maturation is obviously different from that of the supplement test 12B, and the maturation rates of the three transportation times are 46.4%, 37.0% and 28.7% respectively.
In a supplemental test (i.e., supplemental test 12F), reference was made to the test conditions for 24 hour transport in supplemental test 12B, supplemental test 12C, supplemental test 12D, and supplemental test 12E, respectively, above, except that a 5.5% carbon dioxide supply was provided during transport; under the test conditions, the maturation rates of the oocytes in vitro are 87.7%, 70.8%, 75.4% and 73.2%, respectively.
The results show that the maturation rate of the oocytes obtained in vitro maturation in the step (1) of the method of the invention under different conditions is obviously different: the high maturation rate can be maintained even when the transport culture solution to which both taurine and zinc gluconate are added is transported for 24 hours under the condition of no carbon dioxide supply, while the maturation rate is considerably low when the culture solution to which both taurine and zinc gluconate are not added is transported under the condition of no carbon dioxide supply. This indicates that the simultaneous addition of the two reagents to the transport medium is very beneficial for the in vitro maturation of oocytes during transport, especially for environments where carbon dioxide is not available during transport.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (10)
1. A transport culture medium for oocytes comprises 50.0mg/L, L mg of alanine 25.0mg/L, L-arginine hydrochloride 70.0mg/L, L-aspartic acid 30.0mg/L, L-cystine dihydrochloride 26.0mg/L, L-glutamic acid 75.0mg/L, L-glutamine 100.0mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10.0mg/L, L-isoleucine 40.0mg/L, L-leucine 60.0mg/L, L-lysine hydrochloride 70.0mg/L, L-methionine 15.0mg/L, L-phenylalanine 25.0mg/L, L-proline 40.0mg/L, L-serine 25.0mg/L, L-threonine 30.0mg/L, L-tryptophan 10.0mg/L, L-tyrosine disodium dihydrate 58.0mg/L, L-valine 25.0 mg/0 mg/L5 mg/L0.01 mg/L0.8 mg/L5 mg/L0.8 mg/L0 mg/L8 mg/L0 mg/L0.8 mg/L8 mg/L2 mg of calcium chloride, 0.0.0 mg/1000 mg/L of vitamin D, 0.0 mg/L0 mg/1.0 mg/1000 mg/L of vitamin E hydrochloride, 0.0.0.0 mg/L0 mg/1.0 mg/L5L, 0.0 mg/L8, 0 mg/L8-L8, 0mg of vitamin D, 0.8, 0 mg/L8, 0mg of vitamin D, 0.8, 0 mg/L8, L8 mg/L8, L2 mg of vitamin D, L8, L2.8, L8, L2 mg/L8, L2 mg of L8, L8, L8, L250ng/mL EGF, 100ng/mL IGF, 10% gentamicin, 55. mu.g/mL sodium pyruvate, 1.2mM/L cysteine, 3mg/mL BSA, 10mM/L HEPES; for example, itAlso contains taurine and zinc gluconate; for example, the concentration of taurine is 30-50 mg/L, such as 40mg/L or 45 mg/L; for example, the concentration of zinc gluconate is 1 to 3mg/L, for example 2 mg/L.
2. A transport medium for oocytes according to claim 1, which is a method for the culture of bovine in vitro fertilized embryos; the method is as claimed in any one of claims 3 to 10.
3. A method for culturing bovine in vitro fertilization embryos comprises the following steps:
(1) collection and in vitro maturation of oocytes
a) Collecting in vitro: taking cow ovaries obtained from slaughterhouses, extracting follicle with 2-8mm on the surface, collecting precipitate, picking out oocyte COCs (i.e. cumulus-oocyte complex) at least containing 3 layers of cumulus cell packages under a stereomicroscope, putting the oocyte COCs into transport culture solution containing HEPES, transporting to a laboratory at 38.8 ℃ without carbon dioxide supply within 24 h; or
a) Collecting living bodies: taking follicular fluid from ovum collection source of living cattle, picking out cumulus-oocyte complexes (COCs) at least containing 3 layers of cumulus cells under a stereomicroscope, putting into transport culture solution containing HEPES, transporting to laboratory at 38.8 deg.C without carbon dioxide supply for 24 hr;
b) washing COCs obtained by the in vitro collection or the living body collection in oocyte maturation culture solution for 1 time, transferring to new maturation culture solution, and culturing for 22-24h under the conditions of 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
(2) in vitro fertilization
Washing mature COCs in a fertilization culture solution for 1 time, transferring the COCs into the fertilization culture solution, and putting the COCs into an incubator for later use;
taking a frozen tubule from liquid nitrogen, and unfreezing in a water bath at 37 ℃; aseptically cutting two ends of the thin tube, injecting semen into 15mL centrifuge tube containing semen preparation culture solution, centrifuging at 328 Xg for 2 times (5 min each time), and discarding supernatant after centrifuging; adding 300 mu L of semen preparation culture solution into the centrifuge tube, re-suspending the sperm precipitate, and taking proper sperm suspension for sperm counting;
adding the calculated volume of sperm suspension into the fertilization culture liquid drop containing the oocyte, and placing the culture disc into an incubator to incubate the sperm and the ovum for 16-20h, wherein the culture conditions are 38.8 ℃, 5.5-6.5% CO2 and saturated humidity;
(3) embryo in vitro culture and preservation
After the in vitro fertilization operation is finished, removing granular cells around the embryo by using an ovum-peeling needle, putting the granules into embryo culture solution for culture, recording the culture condition as the 1 st day of the embryo culture, wherein the culture condition is 38.8 ℃, 6% O2, 88% N2 and saturation humidity, and recording the cleavage rate on the 3 rd day; recording the blastocyst rate on the 7 th day, counting the blastocyst hatching rate (which is the percentage obtained by dividing the number of hatched blastocysts by the number of blastocysts) by the 9 th day, and carrying out quality identification;
washing the available embryo in preservation solution for 3 times, balancing in balancing solution for 10min, transferring into freezing solution, loading into embryo according to 5-stage liquid loading method, marking, cooling to-35 deg.C at 0.5 deg.C/min in program cooling instrument, taking out the tubule of embryo rapidly, and placing into liquid nitrogen for freezing.
4. The method according to claim 3, wherein in step (1) (b), the maturation medium is BY basal medium supplemented with 100mL/LFBS, 10 μ g/mL FSH, 10 μ g/mL LH, 1 μ g/mL E2, 20ng/mL EGF.
5. The method according to claim 3, wherein in step (1) (a), the transport medium comprises: glycine 50.0mg/L, L-alanine 25.0mg/L, L-arginine hydrochloride 70.0mg/L, L-aspartic acid 30.0mg/L, L-cystine dihydrochloride 26.0mg/L, L-glutamic acid 75.0mg/L, L-glutamine 100.0mg/L, L-histidine hydrochloride monohydrate 21.88mg/L, L-hydroxyproline 10.0mg/L, L-isoleucine 40.0mg/L, L-leucine 60.0mg/L, L-lysine hydrochloride 70.0mg/L, L-methionine 15.0mg/L, L-phenylalanine 25.0mg/L, L-proline 40.0mg/L, L-serine 25.0mg/L, L-threonine 30.0mg/L, L-tryptophan 10.0mg/L, L-tyrosine disodium salt dihydrate 58.0mg/L, L-valine 25.0mg/L, ascorbic acid 0.05mg/L, raw material0.01mg/L of a substance selected from the group consisting of 0.01mg/L of choline chloride, 0.5mg/L, D-calcium pantothenate, 0.01mg/L of folic acid, 0.01mg/L of menadione, 0.025mg/L of nicotinamide, 0.025mg/L of nicotinic acid, 0.05mg/L of p-aminobenzoic acid, 0.025mg/L of pyridoxal hydrochloride, 0.025mg/L of pyridoxine hydrochloride, 0.01mg/L of riboflavin, 0.01mg/L of thiamine hydrochloride, 0.1mg/L of vitamin A acetate, 0.1mg/L of vitamin D2, i.e., calcitol, 0.01mg/L of α -tocopherol sodium phosphate, 0.05mg/L of inositol, 200.0mg/L of anhydrous calcium chloride, 0.7mg/L of ferric nitrate nonahydrate, 97.67mg/L of anhydrous magnesium sulfate, 400.0mg/L of potassium chloride, 6800.0mg/L of sodium chloride, 140.0mg/L of sodium dihydrogen phosphate, 0.354mg/L of adenine triphosphate, 0.7mg/L of choline acetate, 0.5mg/L of adenine sulfate, 0.5mg/L of adenine sodium lactate, 0.80 mg/L of adenine, 0.80L of glutathione, 0.80L of adenine, 0.5L of adenine, 0.80L of reduced calcium acetate, 0.20 mg/L of adenine, 0.80L of adenine, 2L of adenine, 2.80L of adenine, 0.80L of adenine, 2L of 3.5L of adenine, 2.5L250ng/mL EGF, 100ng/mL IGF, 10% gentamicin, 55. mu.g/mL sodium pyruvate, 1.2mM/L cysteine, 3mg/mL BSA, 10mM/L HEPES.
6. The method according to claim 3, wherein the concentration of HEPES (4-hydroxyethylpiperazine ethanesulfonic acid) in the maturation medium is 5-15 mmol/L, such as 10 mmol/L; or, in the step (1), the transport culture solution also comprises taurine and zinc gluconate; or in the step (1), the concentration of taurine in the transport culture solution is 30-50 mg/L, such as 40mg/L or 45 mg/L; alternatively, in step (1), the concentration of zinc gluconate in the transport culture broth is 1-3 mg/L, for example 2 mg/L.
7. The method according to claim 3, wherein in step (2), the fertilization medium is an aqueous solution comprising 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM potassium dihydrogen phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 100U/ml penicillin, 100. mu.g/ml streptomycin.
8. The method according to claim 3, wherein in step (2), the semen preparation medium is an aqueous solution containing 112.0mM sodium chloride, 4.02mM potassium chloride, 2.25mM calcium chloride dihydrate, 0.52mM magnesium chloride hexahydrate, 0.83mM potassium dihydrogen phosphate, 37.0mM sodium bicarbonate, 1.25mM sodium pyruvate, 10. mu.g/ml heparin, 4mg/ml Bovine Serum Albumin (BSA), 10mM caffeine, 100U/ml penicillin, 100. mu.g/ml streptomycin.
9. The method according to claim 3, wherein in step (3), the embryo culture fluid comprises: 109.5mM sodium chloride, 3.1mM potassium chloride, 26.2mM sodium bicarbonate, 0.8mM magnesium chloride hexahydrate, 1.19mM monopotassium phosphate, 0.4mM sodium pyruvate, 1.5mM glucose, 5mM calcium half-lactobionate, 2.5 v/v% Fetal Bovine Serum (FBS), 1mM L-glutamine, 2 v/v% essential amino acids, 1 v/v% nonessential amino acids, 3mM glutathione, 0.04 w/v% sodium citrate, 0.02 w/v% maltose in water; the essential amino acid is added by the following amino acids according to the weight proportion: 6.32g of L-arginine hydrochloride, 1.564g of L-cystine dihydrochloride, 2.1g of L-histidine hydrochloride monohydrate, 2.625g of L-isoleucine, 2.62g of L-leucine, 3.625g of L-lysine hydrochloride, 0.755g of L-methionine, 1.65g of L-phenylalanine, 2.38g of L-threonine, 0.51g of L-tryptophan, 1.8g of L-tyrosine and 2.34g of L-valine, wherein the optional amino acids are added in the following weight ratio: 0.89g of L-alanine, 1.5g of L-asparagine monohydrate, 1.33g of L-aspartic acid, 1.47g of L-glutamic acid, 0.75g of glycine, 1.15g of L-proline and 1.05g of L-serine.
10. The method according to claim 3, wherein in step (1), the BY-based culture solution comprises 180-220 mg/L calcium chloride, 0.70-0.75 mg/L ferric nitrate nonahydrate, 380-420 mg/L potassium chloride, 90-100 mg/L magnesium sulfate, 6500-7000 mg/L sodium chloride, 130-150 mg/L monosodium phosphate monohydrate, 2000-2500 mg/L sodium bicarbonate, 40-60 mg/L, L-alanine, 20-30 mg/L, L-arginine hydrochloride, 60-80 mg/L, L-aspartic acid, 25-35 mg/L, L-cysteine hydrochloride monohydrate, 0.10-0.12 mg/L, L-cystine dihydrochloride, 20-30 mg/L, L-glutamic acid, 70-80 mg/L glycine, 20-60 mg/L, L-histidine hydrochloride monohydrate, 0-12 mg/L, L-15 mg/8-hydroxyproline, 0.008-0.0.06 mg/0.8 mg/L methionine, 0.06-0.06 mg/0.06-20 mg/L methionine, 0.06-200 mg/L choline chloride, 0.06-150 mg/L methionine hydrochloride, 0.06-150 mg/L0.06 mg/L0.8 mg/L, 0.06-150 mg/L methionine hydrochloride, 0-150 mg/L0.8 mg/L, 0-150 mg/L choline chloride, 0.06-150 mg/L, 0.8 mg/L0-150 mg/L sodium nitrite, 0.8 mg/L, 0.8-150 mg/L0.8 mg/L sodium nicotinate monohydrate, 0.8-150 mg/L, 0.8-0.0.8-0.8-0.0.8-0.8-0.0.0.8-0.0.8-0.0.0.0.0.0.8-0.0.8-0.0.0.8-0.0.0.0.0.0.0.0.0.8-0.0.0.8-0.0.8-0.0.0.0.0.0.0.0.0.8-0.8-0.0.8 mg/L0.0.8-0.
In the step (1), the BY basal medium is an aqueous solution containing 200mg/L calcium chloride, 0.72mg/L ferric nitrate nonahydrate, 400mg/L potassium chloride, 97.7mg/L magnesium sulfate, 6800mg/L sodium chloride, 140mg/L sodium dihydrogen phosphate monohydrate, 2200mg/L sodium bicarbonate, 50mg/L, L-alanine sodium acetate, 25mg/L, L-arginine hydrochloride, 70mg/L, L-aspartic acid, 30mg/L, L-cysteine hydrochloride monohydrate, 0.11mg/L, L-cystine hydrochloride, 26mg/L, L-glutamic acid, 75mg/L glycine, 50mg/L, L-histidine hydrochloride monohydrate, 21.88mg/L, L-hydroxyproline, 10 mg/isoleucine, 20mg/L, L-leucine, 60mg/L, L-lysine hydrochloride, 70mg/L, L-methionine, 15mg/L, L-phenylalanine, 25 mg/5-proline, 40mg/L, L-serine, 5825 mg/L, L-leucine, 60mg/L, L-lysine hydrochloride, 0.8 mg/L, 0.05mg/L methionine hydrochloride, 0.05mg/L, 27 mg/L methionine hydrochloride, 0.05mg/L adenine, 27 mg/L, 0.05mg/L, 27-arginine hydrochloride, 0.8 mg/L, 27-arginine hydrochloride monohydrate, 0.8-aspartic acid, 0.8 mg/L, 26 mg/L-cysteine hydrochloride monohydrate, 0.8-L, 0.8-cysteine hydrochloride monohydrate, 0.8-L-cysteine hydrochloride monohydrate, 0.27-cysteine hydrochloride, 0.27-L, 0.8-L, 0 mg/L-cysteine hydrochloride, 0.27-cysteine hydrochloride, 0.8-L-cysteine hydrochloride, 0.8-L-cysteine hydrochloride, 0.7-L, 0.7mg/L, 0.8-L, 0.8-L-
In the step (1), the BY basal culture solution also comprises sodium selenite, and the concentration of the sodium selenite is 0.2-0.3 mg/L, such as 0.25 mg/L; and/or the BY basic culture solution also comprises copper sulfate, and the concentration of the copper sulfate is 0.05-0.1 mg/L (calculated BY anhydrous substance), such as 0.075 mg/L.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010082017.1A CN111254109B (en) | 2020-02-06 | 2020-02-06 | Method for in vitro fertilization and embryo culture of bovine oocytes and transport culture solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010082017.1A CN111254109B (en) | 2020-02-06 | 2020-02-06 | Method for in vitro fertilization and embryo culture of bovine oocytes and transport culture solution |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111254109A true CN111254109A (en) | 2020-06-09 |
CN111254109B CN111254109B (en) | 2022-07-08 |
Family
ID=70949247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010082017.1A Active CN111254109B (en) | 2020-02-06 | 2020-02-06 | Method for in vitro fertilization and embryo culture of bovine oocytes and transport culture solution |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111254109B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111718892A (en) * | 2020-06-29 | 2020-09-29 | 内蒙古大学 | Culture solution and method for improving culture efficiency and quality of bovine in vitro embryos |
CN112322579A (en) * | 2021-01-06 | 2021-02-05 | 天津博裕力牧科技有限公司 | Culture solution for cattle in-vitro fertilization and method for improving cattle in-vitro fertilization |
CN112501114A (en) * | 2021-01-06 | 2021-03-16 | 天津博裕力牧科技有限公司 | Method for improving cattle in-vitro fertilization efficiency |
WO2021258423A1 (en) * | 2020-06-22 | 2021-12-30 | 西北农林科技大学 | Serum-free in vitro maturation culture solution for bovine oocytes and oocyte culture method |
WO2023023371A1 (en) * | 2021-08-20 | 2023-02-23 | Vaccine Stabilization Institute | Formulations containing amino acids for stabilizing lipid enveloped viral and non-viral vectors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108728401A (en) * | 2018-06-07 | 2018-11-02 | 天津博裕力牧科技有限公司 | The method of IVF of Oocyte in Bovine Embryo Culture and culture medium used |
CN108728404A (en) * | 2018-06-07 | 2018-11-02 | 天津博裕力牧科技有限公司 | Ox live body or the method for in vitro oocyte collection IVF Embryos culture |
CN108753689A (en) * | 2018-06-07 | 2018-11-06 | 天津博裕力牧科技有限公司 | The method of ox IVF Embryos culture |
KR20190007326A (en) * | 2017-07-12 | 2019-01-22 | 경상대학교산학협력단 | Culture medium comprising ITS and EGF, and method for in vitro culture of bovine embryo |
CN110066764A (en) * | 2019-05-21 | 2019-07-30 | 天津博裕力牧科技有限公司 | Promote the method for ox embryo in vitro culture oocyte in vitro maturation |
CN111269876A (en) * | 2020-02-06 | 2020-06-12 | 天津博裕力牧科技有限公司 | Method for in vitro fertilization and embryo culture by in vivo collection of bovine oocytes |
-
2020
- 2020-02-06 CN CN202010082017.1A patent/CN111254109B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190007326A (en) * | 2017-07-12 | 2019-01-22 | 경상대학교산학협력단 | Culture medium comprising ITS and EGF, and method for in vitro culture of bovine embryo |
CN108728401A (en) * | 2018-06-07 | 2018-11-02 | 天津博裕力牧科技有限公司 | The method of IVF of Oocyte in Bovine Embryo Culture and culture medium used |
CN108728404A (en) * | 2018-06-07 | 2018-11-02 | 天津博裕力牧科技有限公司 | Ox live body or the method for in vitro oocyte collection IVF Embryos culture |
CN108753689A (en) * | 2018-06-07 | 2018-11-06 | 天津博裕力牧科技有限公司 | The method of ox IVF Embryos culture |
CN110066764A (en) * | 2019-05-21 | 2019-07-30 | 天津博裕力牧科技有限公司 | Promote the method for ox embryo in vitro culture oocyte in vitro maturation |
CN111269876A (en) * | 2020-02-06 | 2020-06-12 | 天津博裕力牧科技有限公司 | Method for in vitro fertilization and embryo culture by in vivo collection of bovine oocytes |
Non-Patent Citations (2)
Title |
---|
RAVINDRANATHA, BM等: "In vitro maturation and fertilization of buffalo oocytes: Effects of storage of ovaries, IVM temperatures, storage of processed sperm and fertilization media", 《REPRODUCTION IN DOMESTIC ANIMALS》 * |
王娜等: "影响牛体外胚胎生产效率的因素", 《今日畜牧兽医》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021258423A1 (en) * | 2020-06-22 | 2021-12-30 | 西北农林科技大学 | Serum-free in vitro maturation culture solution for bovine oocytes and oocyte culture method |
CN111718892A (en) * | 2020-06-29 | 2020-09-29 | 内蒙古大学 | Culture solution and method for improving culture efficiency and quality of bovine in vitro embryos |
CN112322579A (en) * | 2021-01-06 | 2021-02-05 | 天津博裕力牧科技有限公司 | Culture solution for cattle in-vitro fertilization and method for improving cattle in-vitro fertilization |
CN112322579B (en) * | 2021-01-06 | 2021-03-12 | 天津博裕力牧科技有限公司 | Culture solution for cattle in-vitro fertilization and method for improving cattle in-vitro fertilization |
CN112501114A (en) * | 2021-01-06 | 2021-03-16 | 天津博裕力牧科技有限公司 | Method for improving cattle in-vitro fertilization efficiency |
WO2023023371A1 (en) * | 2021-08-20 | 2023-02-23 | Vaccine Stabilization Institute | Formulations containing amino acids for stabilizing lipid enveloped viral and non-viral vectors |
Also Published As
Publication number | Publication date |
---|---|
CN111254109B (en) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111254109B (en) | Method for in vitro fertilization and embryo culture of bovine oocytes and transport culture solution | |
CN112501114B (en) | Method for improving cattle in-vitro fertilization efficiency | |
CN111269876A (en) | Method for in vitro fertilization and embryo culture by in vivo collection of bovine oocytes | |
CN113201484B (en) | Method for improving cryopreservation and thawing of bovine in vitro fertilization blastocysts | |
Gasparrini et al. | Enrichment of in vitro maturation medium for buffalo (Bubalus bubalis) oocytes with thiol compounds: effects of cystine on glutathione synthesis and embryo development | |
CN107142239B (en) | Method for improving culture efficiency of bovine in vitro fertilization embryos | |
CN107034173B (en) | Method for culturing bovine in vitro fertilized embryo and culture solution used in method | |
Balasubramanian et al. | Effect of cysteamine supplementation of in vitro matured bovine oocytes on chilling sensitivity and development of embryos | |
Anchordoquy et al. | Influence of vascular endothelial growth factor and Cysteamine on in vitro bovine oocyte maturation and subsequent embryo development | |
CN112980778B (en) | Method for culturing and cryopreserving bovine in-vitro fertilization embryos | |
CN112322579B (en) | Culture solution for cattle in-vitro fertilization and method for improving cattle in-vitro fertilization | |
CN108728404B (en) | Method for culturing in vitro fertilization embryo of bovine living body or in vitro collected oocyte | |
CN108753689B (en) | Method for culturing bovine in-vitro fertilized embryo | |
CN110066763A (en) | Promote the method for ox embryo in vitro culture development of fertilized ova | |
CN108728401B (en) | Method for culturing bovine oocyte in vitro fertilization embryo and used culture medium | |
Jochems et al. | Effect of two ‘progressively motile sperm–oocyte’ratios on porcine in vitro fertilization and embryo development | |
CN110066764A (en) | Promote the method for ox embryo in vitro culture oocyte in vitro maturation | |
CN113151160B (en) | Method for improving cattle in-vitro fertilization efficiency and used freezing medium and thawing medium | |
JP2020185018A (en) | Embryo culture methods and media | |
Songsasen et al. | Effects of β-mercaptoethanol on formation of pronuclei and developmental competence of swamp buffalo oocytes | |
CN112914784B (en) | Bovine embryo segmentation method | |
EP2740790B1 (en) | Composition for embryo culture | |
JP5410782B2 (en) | Medium composition for artificial fertilization | |
CN113151155A (en) | Cutting liquid for bovine embryo segmentation and bovine embryo segmentation method | |
CN113151156A (en) | Method for segmenting bovine embryo and segmentation liquid used in method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 300457 building a, Alexandria, No.3 Haitong street, Binhai New Area Development Zone, Tianjin Boya company Applicant after: Tianjin Limu Biotechnology Co.,Ltd. Address before: 300457 building a, Alexandria, No.3 Haitong street, Binhai New Area Development Zone, Tianjin Boya company Applicant before: TIANJIN BOYU LIMU TECHNOLOGY CO.,LTD. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |